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Abstract 
The relationship between hypertension and cardiovascular morbidity has long been 
recognised. However evidence is mounting implicating hypotension and not 
hypertension as the predominant risk factor for mortality. I demonstrated a 20-30% 
prevalence of intradialytic symptoms and hypotension in children during conventional, 
4 hour haemodialysis (HD) sessions. The declining blood pressure (BP) was originally 
believed to be caused by ultrafiltration (UF) and priming of the HD circuit due to loss of 
fluid from the intravascular space.  However data, largely in adults, challenged this 
hypothesis leading to a new consensus that intradialytic hypotension has a multifactorial 
aetiology. The uraemic milieu triggers a series of events that alters the cardiovascular 
compensatory responses to haemodynamic stresses, however the extent to which these 
physiological responses are impaired and their consequences are unknown and poorly 
understood.   
 
At first I corroborated adult findings that a poor correlation existed between relative 
blood volume changes and intradialytic hypotension in children, supporting the theory 
that fluid removal alone was not responsible for cardiovascular decompensation during 
HD and this assumption was a gross oversimplification of the underlying problem. 
Using a traditional method (endocardial wall motion) and a novel method (Speckle 
tracking 2-dimensional strain) I then measured the regional left ventricular (LV) 
function in children (aged 2 to 17 years) at the start of dialysis and again during peak 
stress at the end of HD. I found rising cardiac troponin I levels in 25% of the cohort and 
reduced regional LV function in all the children examined. The level of dysfunction 
significantly correlated with actual BP, the degree of intradialytic BP fall and UF 
volumes. What remains unclear however is whether the fall in BP was the cause or 
effect of the ischaemic cardiac injury. Finally I investigated dialysis methods for 
abrogating intradialytic morbidy in children treated with four hour HD sessions. A step 
sodium profile from 148mmol/l to 138mmol/l, prophylactic mannitol and sequential 
dialysis were successful, to variable degrees in attenuating intradialytic symptoms or 
hypotensive episodes. Intradialytic midodrine was exclusively used in one patient 
resistant to all other forms of therapy and was found to be the most efficacious in 
supporting the BP and preventing hypotension. 
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Chapter One 
Introduction: Intradialytic Hypotension 
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1.1 Epidemiology 
During haemodialysis (HD) the objective is to remove all the sodium and water that 
accumulates in the inter-dialytic period within the few hours of treatment time. The 
major barrier to achieving this goal is the development of haemodynamic instability, 
manifesting as hypovolaemia related symptoms or intradialytic hypotension. In adults 
this occurs on average in 20-30% treatments1 with a resultant risk of under dialysis from 
recurrent treatment interruptions and patients remaining volume overloaded. There is a 
clear correlation between high blood pressure (BP) and the risk of stroke. Several 
observational studies in patients with essential hypertension also describe a “J” shaped 
curve between diastolic blood pressure (BP) and mortality2. The same trend has been 
described in dialysis patients, with a suggestion that hypertension is associated with 
morbidity but mortality is associated with hypotension3. In adults, patients with pre-
dialysis systolic BP less than 110 mmHg have a fourfold increase in the relative risk of 
cardiac-related death versus those with a systolic BP between 140 to 149 mmHg. Post 
dialysis, patients with systolic BP less than 110 mm Hg had a 2.8-fold increase in 
relative risk for a cardiac-related death compared with patients with systolic BP 140 to 
149 mmHg4 (see Figure 1.1). The difficulty in dialysis patients is establishing accurate 
surrogates of interdialytic BP load. Most commonly BP targets are based solely on pre- 
and/or post-dialysis systolic BP measurements, however Agarwal et al have shown a 
steady rise in systolic and diastolic BP during the interdialytic period that reaches a 
plateau 48 hours after dialysis5. Furthermore both pre- and post-dialysis BP 
measurements were found to be inferior to home BP recordings in predicting left 
ventricular hypertrophy and mortality6. One could therefore postulate that the negative 
association between low BP and adverse outcomes only reflects the use of a poor 
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SBP < 110 mm Hg v 
140 -149mmHg,   
RR = 2.62,P < 0.01 
SBP < 110 mm Hg v 
140 -149mmHg,   
RR = 2.62,P < 0.01 
surrogate marker of afterload or may represent a cohort of patients with cardiac 
dysfunction or impaired cardiovascular reserve during times of stress.    
 
 
 
 
 
Figure 1.1: Systolic blood pressure (SBP) post dialysis and cardio/cerebrovascular mortality in 
haemodialysis patients 4 
 
 
 
Frequent intradialytic hypotensive episodes have also been implicated in accelerating 
decline in residual renal function and precipitaing serious vascular complications such 
as cerebral, cardiac and mesenteric ischaemia. The problem is confounded in children as 
the ultrafiltration (UF) goal is often higher from liquid nutritional supplements or poor 
adherence to fluid restrictions. In addition younger or developmentally delayed children 
may not be able to verbalize the evolution of new symptoms and therefore there can be 
very little warning of decompensation. This places a greater reliance on monitors and 
basic cardiovascular measurements during their treatments.  
 
 
 
Systolic BP mmHg 
SBP 110-119 v     
140-149mmHg,  
RR= 1.48 (p<0.01) 
SBP < 110 mm Hg v 
140 -149mmHg,   
RR = 2.62 (p< 0.01) 
 
SBP >180 v  140-149mmHg,  
RR= 1.06 (p<0.05) 
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1.2 Definition 
There is no recognised definition of intradiaytic hypotension in children. Very loosely 
the term refers to a drop in BP during dialysis and has been defined by KDOQI as a 
decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by 10 mm Hg 
associated with symptoms7. The former is such a non-specific, subjective definition and 
unsuitable in the research arena. The latter in our opinion is not always relevant in the 
paediatric environment. In children the evolution of symptoms can be for a number of 
reasons but if a hypertensive patient had a 25mmHg fall in systolic BP that restores their 
BP to within the normal range, despite being a clinically a favourable outcome this will 
still be categorised as an episode of intradialytic hypotension and thus a negative 
dialytic outcome. Therefore at the onset of this work I elected to develop a clinically 
valid, objective and reproducible definition relevant to paediatrics.  
 
The first task force on blood pressure control in children is the only group to report age 
and gender adjusted 5th percentile systolic blood pressure measurements from the 
general population8. For the purpose of this study, I defined intradialytic hypotension as 
any BP measurement below the 5th percentile systolic blood pressure measurements as 
this is equivalent to a BP below that expected within the normal population. Any 
deviation from this is clearly stated in the text.  
 
 
1.3 Pathophysiology  
During dialysis mobilization of fluid from the interstitial to the intravascular space, 
venoconstriction of capacitance vessels, increased vascular tone and active increases in 
heart rate and contractility preserve circulatory adequacy. As a result even with a UF 
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volume equal to the entire plasma volume the measured blood volume only changes by 
10-20%. An impaired compensatory response causes hypotension in the face of total 
body water expansion. 
 
Most of the plasma volume resides in the veins, with a marked difference in the venous 
capacitance between organs. During UF the ability to mobilize blood from the 
splanchnic venous pool is vital for preserving the central blood volume. Venous tone is 
affected by vasoactive hormones, sympathetic nervous system and upstream filling 
pressures. The De-Jager Krogh phenomenon refers to the transmission of upstream 
arterial pressure through the capillaries to the veins causing venous distension and 
altered venous capacitance. During arteriolar constriction the distending pressure to the 
vein is reduced and blood is extruded centrally towards the heart to maintain cardiac 
refilling. Conversely factors that cause arterial dilatation, such as antihypertensives 
increase venous capacitance, reduce cardiac filling pressures and through transmission 
of increased hydrostatic pressure to the capillary bed inhibit vascular refilling.  
 
Vasoconstriction is mediated by an increase in sympathetic activity. In dialysis patients 
this response can be inadequate owing to an increased production of vasodilators or 
impaired sympathetic response to hypovolaemia. Adenosine is an endogenous 
vasodilator that is released by vascular myocytes and endothelial cells. It is 
hypothesized that during a sudden, non-gradual intradialytic hypotension episode, 
ischaemia prevails resulting in increased consumption of adenosine triphosphate (ATP) 
and generation of adenosine9. This is thought to augment splanchnic blood pooling 
through an inhibitory effect on norepinephrine release thus causing regional 
vasodilatation, result in arteriolar vasodilatation and depress myocardial contractility. In 
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fact, pretreating hypotensive prone patients with caffeine, an adenosine receptor 
antagonist, was shown to lower the number of hypotensive episodes in adults10. 
Additional mediators of tone include nitric oxide and asymmetrical dimethyl arginine 
(ADMA). During dialysis elevated levels of cytokines such as interleukin 6 and tissue 
necrosis factor alpha stimulate synthesis of inducible nitric oxide synthetase within 
vascular smooth muscle cells and thus an increased production of nitric oxide, a potent 
vasodilator. However the increase in nitric oxide concentration is delayed by hours after 
the initial exposure to the cytokines and is also accompanied by the continued removal 
of competitive inhibitors of nitric oxide synthetase such as ADMA11 during HD. Such 
enhancement of endothelial function hours into dialysis is though to contribute to the 
evolution of late onset intradialytic hypotension. 
 
 The sympathetic nervous system is the principle control mechanism of arteriolar tone 
and therefore of central blood pressure and patients with end stage renal disease (ESRD) 
show increased basal level of peripheral sympathetic activity10, 12. In hypotensive prone 
patients a paradoxical decrease in sympathetic activity is seen at the time of a 
hypotensive episode12 and this results in a rapid decline in the peripheral vascular 
resistance and increased vascular bed capacitance. Problems with sympathetic end-
organ responsiveness and the efferent parasympathetic baroreceptor pathway have also 
been reported but the underlying mechanism remains unexplained. Some believe this 
may be a heightened manifestation of the Bezold-Jarisch reflex, a cardiodepressor reflex 
resulting in a sudden loss of sympathetic tone causing abrupt severe hypotension 
accompanied by bradycardia. It is postulated that conditions associated with reduced 
cardiac refilling pressures such as left ventricular hypertrophy, diastolic dysfunction or 
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structural heart defects stimulate cardiac stretch receptors and thus maladaptively trigger 
a variant of the Bezold-Jarisch resulting in hypotension.   
   
The remaining key player and interconnecting component is plasma refilling. This refers 
to the movement of fluid from the extravascular to the vascular compartment under the 
influences of hydraulic, osmotic and oncotic pressure gradients across the capillary bed. 
If UF rates exceed refilling rates the intravascular volume will fall. There is evidence of 
increased capillary permeability in the presence of uraemia that encourages movement 
of water between the interstitium and intravascular compartments13. Arterial 
vasoconstriction decreases hydrostatic pressures on the capillary bed, facilitating 
vascular refilling. The oncotic pressure which is effectively the plasma protein 
concentration promotes refilling; and plasma sodium and glucose mobilizes fluid from 
the intracellular space as a result of increased plasma tonicity14. Plasma haematocrit 
level has a positive influence on refilling rates, however during dialysis plasma 
haematocrit levels change as early as 15mins secondary to change in posture, 
haemodilution caused by redistribution of water from the extra- to the intravascular 
space and redistribution of blood from the microcirculation to the central circulation, the 
Fahraeus effect15. Finally refilling is facilitated by greater tissue hydration and occurs at 
a faster rate when the interstitial space is overloaded. 
 
There are also a number of additional factors that may influence the central blood 
pressure during dialysis. Firstly the volume of blood that is required to support the 
extracorporeal circuit can be a significant proportion of the effective circulating volume 
in the younger patients. Blood and dialyser membrane reactions can result in a 
significant inflammatory response and early decompensation, with some evidence 
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suggesting cellulosic membranes to be greater offenders in activating complement and a 
number of cytokine systems than synthetic membranes. The choice of anticoagulant can 
also influence intradialytic BP with reports of hypotension with regional citrate and 
prostanoid anticoagulation compared with heparin and low molecular weight heparins.  
 
In essence we know that hypovolaemia is the trigger for intradialytic hypotension but 
the pathophysiology is complex and the current explanation is incomplete. The uraemic 
milieu impairs compensatory responses to reduced blood volume with ineffective 
venoconstriction, inadequate cardiac refilling, reduced plasma refilling and activation of 
the sympaticoinhibitory Bezold–Jarish reflex leading to sudden hypotension. The 
literature is dominated by research in adults and the degree to which this can be 
extrapolated to paediatrics is unknown. We have anecdotal evidence that children on 
conventional HD regimens develop intradialytic hypotension but lack published data on 
the prevalence, pathophysiology and consequences of intradialytic hypotension that is 
specific to paediatrics 
 
 
1.4 Risk Factors  
1.4.1 Dialysis Related 
The dialysate composition can influence cardiovascular stability during HD. Dialysate 
sodium generates a crystalloid osmotic pressure and promotes fluid shift between the 
different body compartments. Dialysate sodium activity is approximately equal to 97% 
of the measured sodium concentration, but varies with changes in dialysate temperature, 
pH and the presence of additional ions.  In the absence of UF, we can approximate the 
concentration of dialysate sodium to achieve isotonic dialysis by correcting the blood 
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sodium measured by direct ionometry for a Donnan factor of 0.967. Hyponatric dialysis 
causes osmotic fluid shift from the extracellular to intracellular compartment, dialysis 
disequilibrium disorder and intradialytic hypotension. Hypernatric dialysis transfers 
sodium to the patient, causing interstitial oedema, interdialytic thirst and increased 
interdialytic weight gain but may also achieve short-term dialysis gains by improving 
cardiovascular stability.  
 
Hypocalcaemia depresses myocardial contractility and reduced vascular reactivity16 and 
thus increases the risk of intradialytic hypotension. Conversely owing to fear of 
inducing extra-skeletal calcium deposition, the new K/DOQI guidelines suggest 
maintaining plasma calcium levels in the low normal range. Using a dialysate calcium 
concentration of 1.25mmol/l permits higher vitamin D and calcium based phosphate 
binders in the management of hyperparathyroidism. In a proportion of patients this can 
lead to hypocalcaemia17. Low magnesium dialysate baths will encourage the movement 
of plasma magnesium molecules across the dialysis membranes. Low plasma 
magnesium levels can result in cramping and arrhythmias and higher magnesium baths 
may help to improve cardiovascular stability and intradialytic symptoms. Acetate was 
originally used as the buffer in dialysate as it was cheap, offered equimolar conversion 
to bicarbonate and is bacteriostatic. However high plasma acetate levels result in 
vasodilatation, depressed left ventricular function and thus place individuals at risk of 
intradialytic hypotension and hypoxaemia particularly in the first hour of dialysis18. 
Switching to bicarbonate buffers improves cardiovascular stability.    
 
During fluid removal from the vascular compartment venoconstriction of the splanchnic  
and possibly the splenic19 vascular beds, mobilizes blood, forcing it centrally towards 
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the heart to maintain cardiac refilling. If food is consumed during dialysis, blood is 
diverted to the splanchnic circulation and patients are susceptible to intradialytic 
hypotension.   
 
1.4.2 Uraemic Cardiovascular Disease 
The cardiovascular mortality rate of children and young adults on dialysis is extremely 
high, at 1000 times greater than age-matched controls20 and greater than adult dialysis 
patients.  
 
Figure 1.2: All cause cardiovascular mortality for men and women in the general population and 
those on haemodialysis 20 
 
The pathophysiology of uraemic cardiac disease is not fully defined but patients with 
ESRD are exposed to a number of traditional and non-traditional cardiovascular risk 
factors. Cardiovascular morbidity and mortality was originally thought to be a problem 
exclusive to adult dialysis patients however opinions are changing. Children in ESRD 
share the full gamut of uraemia related cardiovascular abnormalities as adults but 
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distinct differences exist that may be important in the context of considering 
cardiovascular stability during HD. 
 
Children do not share the high prevalence of traditional Framingham risk factors as 
adults and neither have they developed significant classical, atheromatous, coronary and 
peripheral artery disease. What is unclear however is whether the absence of 
macroscopic, atheromatous vasculopathy translates to improved dialysis morbidity over 
adults. Theoretically with less advanced cardiovascular disease children should be able 
to tolerate larger UF goals without decompensation and tolerate a more aggressive 
approach towards UF without running the risk of adverse ischaemic injury. However 
there is clear evidence of significant cardiovascular disease in children on dialysis. 
Mechanical or haemodynamic overload21, 22 and altered humoral responses23, 24 are 
precursors for cardiac remodeling and the development of left ventricular hypertrophy 
(LVH). Echocardiogram studies have demonstrated significantly worse diastolic 
dysfunction in children on HD and peritoneal dialysis (PD)25-27 compared with those 
with mild-to-moderate chronic kidney disease (CKD) or post transplant27, 28 but the 
systolic function is preserved. The presence of vascular disease is demonstrated by 
reports of reduced vascular compliance29, 30 and recent studies describing transformation 
of paediatric vascular smooth muscle cells into osteoblast-like cells with subsequent 
calcification of coronary valves, carotid and coronary arteries and increased vessel 
intima-media thickness31-33. These vascular abnormalities are accepted markers of 
asymptomatic atherosclerosis and predictors of future symptomatic CVD in adults with 
CKD34, 35 and although no such data exists in paediatrics it raises a strong suspicion for 
a maladaptive cardiovascular system in children.  
 
  
26
Over and beyond the presence of uraemia, there is a now a growing body of evidence 
incriminating HD as an independent contributor to endothelial dysfunction. HD is pro-
inflammatory presumably due to an immune mediated response to non-biocompatible 
membranes, blood contact with non-sterile dialysate solution and/or "back-leaking" of 
dialysate across the membrane. However the mechanisms by which CRP production is 
stimulated still eludes us. More frequent dialysis therapies are associated with improved 
CRP levels and other markers of inflammation36, 37 but in contrast during conventional 
HD elevated C-reactive protein (CRP) levels correlate with dialysis vintage38.  Not only 
is CRP a valid marker of cardiovascular impairment and atherosclerosis in ESRD but is 
itself thought to pathogenic. It is produced specifically by coronary artery smooth 
muscle cells and directly contributes to vascular inflammation and atherosclerosis39.. 
Finally HD is also associated with changes in blood volume, blood viscosity and 
laminar shear stress. This is an environment conducive to disordered endothelial cell 
dynamics and function and ischaemic injury. 
 
Cardiovascular disease in paediatric dialysis patients is driven by a variety of factors 
different to those in the general population: peripheral vascular changes, calcification, 
inflammation and possibly the dialysis procedure itself. However it is difficult to 
distinguish what is cause or effect in the evolution of intradialytic hypotension and what 
part, if any, repetitive HD induced ischaemic injury plays in the pathogenic process in 
children.  
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1.5 Paediatric Haemodialysis 
Technically paediatric HD refers to the dialysis of children from birth to 18 years of 
age. The basic principles of dialysis are universal but the dialysis prescription has to be 
tailor-made for each child and is often adjusted according to the patient’s body surface 
area. A conventional paediatric HD schedule consists of four hour treatments, 3 times 
per week or three hour treatments, four times per week. Vascular access is achieved 
either through a tunneled, indwelling catheter such as a permcath or an arteriovenous 
fistula. During infant dialysis if the volume of the extracorporeal circuit volume is 
greater than 10% of the estimated total blood volume (TBV) a circuit prime with 5% 
albumin or blood is recommended.   
 
 
 
 
Figure 1.3: Schematic diagram of a haemodialysis circuit 
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With increasing blood flow, more solute is delivered to the dialyzer, resulting in higher 
dialyser clearance but this clearance advantage starts leveling off at blood flows of 250-
300mls/min and therefore where possible a blood flow rate as close to 300mls/min is 
used. In children however the effective blood flow rate is largely determined by the 
vascular access and adjusted to achieve a 4-6mls/kg/min urea clearance, approximating 
a Kt/V of > 1.2 40, or in infants a minimum of 20mls/min to avoid the risk of clotting the 
circuit. The problem with small, high resistance double-lumen central venous catheters 
or occasionally single lumen catheters is an increased risk of high recirculation rates 
with inadequate dialysis on conventional dialysis regimens. This can be improved by 
changing the dialysis time by increasing the frequency or duration of treatment.  
 
As a general rule to maximise effective dialyser clearance the ratio between dialysis 
fluid and blood flow should be at least 1.5 to 2 and in children typically dialysis flow 
rates of 300-500mls/min are employed, even in infants with low blood flow rates. The 
dialysate temperature is most commonly set at a constant temperature of 37˚C. 
Bicarbonate is now routinely used as the acid buffer and intravenous heparin 
anticoagulates the extracorporeal circuit. With a desired objective of achieving long-
term solute balance the dialysate sodium, magnesium, calcium and potassium 
composition can be adjusted in accordance with the patient’s plasma levels.  
 
 
1.6 Cardiovascular Response to Haemodynamic Stress 
During HD both UF and plasma solute clearance induces fluid exchange that ultimately 
results in intravascular fluid depletion. This haemodynamic stress triggers a 
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characteristic compensatory response which owing to differences in physiological 
maturity is age dependent but is ultimately aimed at restoring circulation adequacy.   
 
In general the cardiac output is predominantly determined by the heart’s loading 
conditions. Preload is defined as the ventricular wall tension at the end of diastole and is 
largely derived from the circulating blood volume and venous capacitance. The velocity 
and power of contraction in single fibres is directly related to fibre length at the 
beginning of contraction (The Frank-Starling law). As the preload increases the stroke 
volume (SV) increases but there is a limit of preload reserve. Conversely, as is the case 
during HD, as the preload decreases the SV decreases. Afterload is the sum of forces 
opposing ventricular ejection and the most important component is total peripheral 
resistance (TPR) or systemic vascular resistance. SV decreases as afterload increases 
but by increasing the contractility of the heart some gain in SV can be achieved. Heart 
rate (HR) increases cardiac output but by reducing the time spent in diastole rapid rates 
can decrease SV by limiting ventricular filling and reducing coronary arteries perfusion. 
As SV increases the myocardial demand for oxygen rises and coronary blood flow must 
rise to compensate. Finally in a response to reduced cardiac output, vascular tone is 
increased in attempt to preserve the central blood pressure and maintain vital organ 
perfusion. 
 
Ventricular compliance is also an important component of cardiac output. Ventricular 
filling occurs in two stages, the rapid early filling which is associated with ventricular 
relaxation and then the slower later filling that is augmented by atrial contraction. As 
ventricular compliance decreases the end-diastolic volume for a given end-diastolic 
pressure falls and is in these circumstances the slow phase dominates. An increase in 
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heart rate will accelerate the rate of relaxation and may precipitate a fall in cardiac 
output. Similarly ischaemia compromises the rate and extent of relaxation.  
 
Neonates at the time of birth have reduced inotropic and preload reserve and thus their 
dominant response to a haemodynamic challenge is tachycardia. The sympathetic 
innervation of the neonatal heart is less well developed than the parasympathetic and 
thus they have a propensity for reflex bradycardia. Compared with older children any 
fall in HR is accompanied by an attenuated vasoconstriction response and 
disproportionately larger decreases in cardiac output. Therefore as afterload increases 
cardiac output falls but in the reverse as the afterload falls there is a less impressive gain 
in output. In infancy and childhood the myocardium adapts progressively and develops 
an increased reserve to B adrenergic stimulation. 
 
Stressors such as HD cause intravascular fluid depletion. As the effective circulating 
volume falls, the preload, SV and cardiac output would fall. In an attempt to maintain 
the central BP one would expect a local hormonal, metabolic and sympathetic stimulus 
increases vascular tone and total peripheral resistance. In the presence of arteriolar 
constriction the distending pressure to the vein is reduced and blood is extruded 
centrally towards the heart to maintain cardiac refilling.  
 
Uraemia is associated with a maladaptive cardiovascular response but what is unknown 
in paediatrics is the extent to which the processes described above are abnormal. 
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1.7 Blood Volume Monitoring and Ultrafiltration 
On-line non-invasive blood volume monitors (NIVM) make it feasible to indirectly 
measure blood volume, both real-time and continuously throughout dialysis. They are 
based on the principle of mass conservation: the concentration of measured blood 
constituents (haemoglobin/haematocrit/plasma protein) confined to the vascular space, 
change in proportion to changes in the vascular volume. It is also assumed that the total 
concentration of blood constituent in the circulation is constant with uniform mixing 
throughout the vascular space. NIVMs differ by the intrinsic sensing techniques that are 
used for monitoring. 
 
Optical: measures the optical absorbance of monochromatic light, via an optoprobe in 
the arterial line. The optical density of whole blood is really a measure of red blood cell 
(RBC) concentration - the haematocrit, rather than the haemoglobin content. Scattering 
of light from the surface of RBC yields a non-linear relationship between the measured 
optical density and hematocrit. The Crit-line (In-Line Diagnostics, Riverdale, Utah), a 
stand alone device, is however designed to correct for this while the Hemoscan (Hospal-
Dasco, Medolla, Italy) which forms part of the dialysis machine, adjusts for variations 
in oxygen saturation.   
 
Blood density: blood density is dependent on the total protein concentration (plasma 
protein concentration + mean cellular haemoglobin concentration). The Blood Volume 
Monitor (BVM, Fresenius AG, Bad Homburg, Germany) measures the velocity of 
sound through blood, by means of a cell inserted in the pre-pump segment of the arterial 
line, adjusted for temperature, a factor known to impact on both sound velocity and 
blood density.  
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Electrical conductance: conductivity of blood depends on hematocrit, temperature, 
plasma electrolytes and non-electrolyte concentrations. The difference of high and low 
frequency conductivity has been found to be a measure of hematocrit. The 
extracorporeal plasmatic impedance meter (IPEC, Laboratoire Eugedia, Chambly, 
France) translates changes in conductivity into relative changes in the plasma volume. 
 
All three devices report results as a percentage relative change of the blood volume 
(RBV), and in some, these are displayed graphically. Each device is fitted with 
computer software that converts measured changes to percentage RBV based on an 
internal calibration reference points. These may differ between machines and therefore 
an absolute RBV value on one device may not read the same on another. Schneditz et al 
demonstrated a 2% difference in relative blood volume changes (BVM 2% less 
reduction in blood volume compared to Crit-line), which developed approximately 1 hr 
into dialysis, and persisted thereafter 41.   
 
NIVM measures the change in blood volume as fluid is being removed during UF and 
thereby provides additional insight into vascular refilling ability. Theoretically, this 
could guide UF rates based on observed RBV changes as demonstrated by the four 
relative blood volume (RBV) curves shown in Figure 1.4.  
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Figure 1.4: Examples of relative blood volume curves taken during haemodialysis 
 
 Patient 1 has a flat line throughout dialysis and hence plasma refilling rate is 
able to fully compensate UF rates. In fact one could assume the patient has an 
excess of fluid in the interstitial space as refilling rates remain high throughout 
dialysis. It is thus probable that the patient will tolerate higher UF rates. 
 Patient 2 has a constant RBV curve during a first part of dialysis followed by a 
linear decrease. This would indicate compensated UF up to the point that the 
curve is flat but thereafter the plasma refilling rate is not able fully compensate 
UF rate and thus the RBV falls. 
 Patient 3 shows a linear decrease of RBV from the onset of dialysis with a 
constant declining slope. In this patient the UF rate is always exceeding the 
plasma refilling rate and therefore if the UF rate was to be increased there is a 
risk of precipitating decompensation. 
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 Patient 4 shows a linear decrease of RBV with a variable declining slope. In this 
patient fluid removal is too rapid at the onset as demonstrated by the steep 
decline in RBV and the risk of symptoms secondary to hypovolaemia is high. 
The UF rate needs to be revised to reduce intradialytic morbibity. 
 
Steuer et al achieved a 2-fold reduction in intradialytic symptoms using NIVM in six 
hypotension prone adults, without changing the UF volume or treatment times42. 
Additional benefits that have been reported in adults are an increase in the UF potential, 
lowering of the dry weight, improved patient well-being and reduced hospitalization 
due to fluid overload. Access to information on blood volume status would be 
particularly helpful in the paediatric HD setting as the prevalence of intra- and 
interdialytic morbidity can be higher when children do not often verbalize early warning 
symptoms and for differentiating between symptoms caused by aetiologies other than 
hypovolaemia.  Responding directly to RBV changes with RBV driven algorithms have 
shown decreased UF associated symptoms and antihypertensive medication burden, 
with the greatest impact on children weighing less than 35 kg43-45. Michael et al defined 
a safe UF rate based RBV change of < 8 % per hour in the first 90 mins and then < 4 % 
thereafter, with no more than a 12 % net RBV change per dialysis session44 but there is 
no data on the predictability of RBV levels of impending intradialytic symptoms or 
hypotension in paediatrics. Adult literature has been more comprehensive and results 
have been conflicting. Kim initially showed46 that if RBV fell below a given threshold, 
arterial hypotension appeared. Subsequently, larger observational studies demonstrated 
that critical maximal RBV reduction had no predictive power but found that irregularity 
of the RBV curve and switching from an exponential to a linear decrease were the most 
powerful predictors of intradialytic hypotension47, 48.  
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1.8 Myocardial Architecture and Function 
1.8.1  Myocardial Contraction 
The muscle of the heart is layered in a helical arrangement with complex spatial 
organization of the left ventricle (LV) myocardial fibres49. Cardiac muscle is not a 
homogeneous muscle mass, but shows variations at a microscopic level between 
individuals and further changes arise from disease states. Circumferentially oriented 
myocardial fibres form the largest proportion of fibres and are primarily found in the 
midwall layer and longitudinally oriented fibres are primarily found in the endocardial 
and epicardial layers 50(see figure 1.5). 
 
Three perpendicular axes define the local myocardial fibre direction of movement: 
radial (R), circumferential (C), and longitudinal (L) as shown in Figure 1.6. The 
circumferential axis is tangent to the surface and oriented in the short-axis direction for 
both the epicardium and endocardium; the longitudinal axis is tangent to the surface and 
oriented in the cardiac long axis; and radial axis lies in the direction perpendicular to the 
wall and is tilted near the apex because of the taper of the LV. 
 
 
 
 
Figure 1.5: MRI reconstruction of ventricular muscle fibre orientation 51 
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Figure 1.6: Diagram illustrating the direction of local myocardial fibre arrangement and 
resultant deformation 52 
 
 
Myocardial contraction is a complex three-dimensional motion. At the macroscopic 
level a combination of wall (radial) thickening, circumferential shortening, and 
longitudinal shortening occurs. Consequently ejection is combined effect of the inward 
pressure generated from concentric forces when these muscle layers start to tense and 
longitudinal shortening. The LV apex rotates counter clockwise (as viewed from the 
apex) and the base rotates clockwise creating a torsional deformation from oppositely 
wound epicardial and endocardial myocardial fibres. Internal cardiac fibres moved to 
the outside and those on the outside move to the inside. The reverse happens in diastole. 
The resultant effect is a twisting motion, like a wet cloth being wrung out with the apex 
fixed while the base of the heart ‘screws down’ onto the apex. Changes in the 
intracavity volume occur as a result of the inward motion and deformation 
(circumferentially and longitudinally) of the endocardium. Both the circumferential and 
longitudinal shortenings contribute to the magnitude of the ejection fraction 53 but in 
normal individuals midwall circumferential fibre shortening appear to be the most 
important component.  
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During systolic ventricular contraction the subendocardial coronary vessels, namely the 
vessels that enter the myocardium, are compressed due to the high intraventricular 
pressures. However, the epicardial coronary vessels, the vessels that run along the outer 
surface of the heart, remain patent. Because of this, blood flow in the subendocardium 
stops. As a result most myocardial perfusion occurs during heart relaxation (diastole) 
when the subendocardial coronary vessels are patent and under low pressure. 
 
1.8.2 Coronary circulation 
The major vessels of the coronary circulation are the left main coronary that divides into 
left anterior descending and left circumflex branches, and the right main coronary 
artery. Both of these arteries originate from the root of the aorta, immediately behind the 
aortic valve leaflets,left coronary artery originates from the left aortic sinus, while the 
right coronary artery originates from the right aortic sinus.  
 
 
Figure 1.7: Coronary circulation 
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The coronary arteries sub-divide to form three compartments. Firstly the proximal 
compartment which constitutes the large epicardial coronary arteries. These lie on the 
surface of the heart, large capacitance function and offer very little resistance to 
coronary blood flow but are responsive to flow mediated dilatation. Their anatomical 
blood supply to regions of the heart is shown in Table 1.1; nonetheless the exact 
anatomy can vary considerably between individuals, especially in the apical cap.  
 
Table 1.1: Anatomical blood supply to regions of the heart 
Anatomic Region of 
Heart 
Coronary Artery (most 
likely associated) 
Inferior 
Infero-septal 
Right coronary  
Anterior 
Antero-septal 
Left anterior descending 
Infero-lateral  
Antero-lateral 
Left circumflex 
 
The coronary arteries then divide into pre-arterioles. These vessels maintain the pressure 
within a narrow range when coronary flow or intravascular pressure varies. They are 
essentially the principle site of autoregulation. The vessels then finally divide into 
intramural arterioles with diameters less than 100µm serve to ensure that myocardial 
blood supply adequately meets the metabolic demand of the heart. Their role is the 
metabolic regulation of coronary blood flow and these dilate in response to various 
metabolic stimuli.  
 
The objective of the combined autoregulatory mechanisms within the coronary 
circulation is to match blood flow with myocardial oxygen consumption and this is done 
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principally by coordinating vascular tone and resistance. There is a degree of reserve 
within the system, the coronary flow reserve and this refers to the magnitude of the 
increase in coronary flow that can be achieved in going from basal coronary perfusion 
to maximal coronary dilatation. 
 
 
1.8.3 Echocardiography  
Two dimensional (2D) echocardiography use ultrasonic waves directed perpendicularly 
to the heart to provide real-time imaging of the heart. This also provides the means to 
assess cardiac function non-invasively. Global LV systolic function is usually assessed 
by the resting LV ejection fraction (LVEF), expressed as the ratio of the stroke volume 
divided by the end-diastolic volume.  
   Stroke volume (SV) = LV end-diastolic volume - LV end-systolic volume 
   LVEF (%) = (SV / LV end-diastolic volume) x 100 
 
 
In order to assess regional LV systolic function the heart has to be divided into 
segments. A standardised 17 segment model recommended by The American Heart 
Association (AHA)54, names segments according to their location relative to the long 
axis of the ventricle and 360° circumferential locations on the short-axis views as shown 
in Figure 1.8. In spite of the probable variability in the coronary artery blood supply to 
myocardial segments, a consensus has been reached on assigning the 17 myocardial 
segments to the territories of the left anterior descending (LAD), right coronary artery 
(RCA), and the left circumflex coronary artery (LCX) (see Figure 1.9) with a note of 
caution that the greatest variability in myocardial blood supply occurs at the apical cap, 
segment 17. 
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Figure 1.8: Left ventricle Segmentation54  
 
 
Figure 1.9: Assignment of the 17 myocardial segments to the territories of the left anterior 
descending (LAD), right coronary artery (RCA) and the left circumflex coronary artery (LCX). 
The greatest variability in myocardial blood supply occurs at the apical cap, segment 17 54.  
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Regional myocardial contractile function can be assessed by measuring myocardial wall 
motion measurements (displacement and velocity) or wall deformation (strain). The 
term "strain" refers to the fractional or percentage change from the original, unstressed, 
dimension or the change in length corrected for the original length. In common terms, 
deformation of a heart fibre is akin to stretching of the heart fibre. Myocardial strain is 
dimensionless and usually shown as a percentage. Through the assessment of segmental 
myocardial strain the contraction/relaxation pattern of the LV can be followed in 3 
planes; longitudinal, circumferential, and radial. In comparison routine 
echocardiographic assessment of regional wall motion activity will only provide 
information on longitudinal axis function.  
 
 
1.9 Myocardial Stunning  
1.9.1 Definition  
 Myocardial stunning is defined as transient, post-ischaemic, left ventricular 
dysfunction with normal or near- normal myocardial perfusion 55 
 Episodes of transient myocardial ischaemia can be followed by reversible left 
ventricular (LV) dysfunction, namely reduced or absent contraction in global or 
discrete parts of the LV 
 
1.9.2 Evidence for haemodialysis induced myocardial stunning 
In order to establish whether HD induces myocardial stunning three criteria needed to 
fulfilled, intradialytic i) myocardial ischaemic injury, ii) reduced myocardial blood flow 
and iii) segmental or global LV dysfunction. I present the evidence for all three of these 
criteria in adult HD patients. 
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Short intermittent HD treatments cause significant hypovolaemia and intradialytic 
hypotension (IDH)56, 57. Acute rise of cardiac troponin-T (cTnT) levels following 
dialysis has been speculated to indicate subclinical myocardial cell injury58, 59. This 
parallels several studies demonstrating silent ST segment depression during dialysis at 
rates that vary between 15 and 40%60. In addition to cTNT, brain natriuretic peptide 
(BNP) is gaining increasing recognition as a marker of acute myocardial cell damage. 
There is evidence that a combination of elevated BNP, in combination with elevated 
markers of inflammation such as interleukin 6 (IL-6), predicts stunned myocardium, 
whereas elevated BNP with normal IL-6 levels correlate with non-viable, infarcted 
myocardium61. In addition, elevated BNP levels predict mortality in dialysis patients62. 
Elevated biomarkers of myocardial damage have also been demonstrated in children 
with chronic kidney disease63.  
 
Although there was initial debate as to whether these biochemical and 
electrocardiographic abnormalities reflect silent ischaemia or changes in electrolyte 
concentrations, subsequent studies measuring myocardial blood flow strengthen the 
case for ischaemia. Using single photon emission computed tomograghy dialysis 
induced perfusion defects have been demonstrated64. In a small cohort of patients with 
and without large vessel epicardial coronary disease, regional myocardial blood flow 
fell. The segments demonstrating, transient, intradialtyic LV dysfunction also exhibited 
the greatest reduction in regional myocardial blood flow. The duration of LV 
dysfunction extended beyond the period of reduced perfusion and was thus more in 
keeping with myocardial stunning than stress cardiomyopathy (see Figure 1.10 and 
1.11).  
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Figure 1.10:  HD is associated with both reduced global and segmental myocardial blood flow 
(MBF) 65  
 
 
 
 
Figure 1.11 Stunned myocardial segments exhibit significantly greater reduction in myocardial 
blood flow (MBF) 65 
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One method of examining regional LV function is through echocardiographic 
assessment for the development of new LV regional wall motion abnormalities 
(RWMA). New RWMAs are indicative of ischaemia and their onset precedes symptoms 
and electrocardiographic changes. These principles form the basis and rationale for 
dobutamine stress echocardiography66. In 75% of prevalent adult HD patients new 
RWMAs have been demonstrated, starting 2 hours into dialysis, peaking at the time of 
maximum stress at the end of dialysis, with 30% persisting 30 minutes postdialysis. A 
direct correlation is seen between both the number and intensity of stunning within 
segments and intradialytic BP changes and UF volume67. A study of sequential positron 
emission tomography (PET) scans of adult during their HD treatment reported a 13% 
reduction in global myocardial blood flow 30 minutes into HD, a period of minimal UF. 
This was accompanied by a 5% fall in cardiac output but no change in systolic and 
diastolic BP or heart rate was observed. By 220 minutes the global myocardial blood 
flow had fallen on average by 26% with a corresponding 21% drop in cardiac output, a 
significant tachycardic response but again a non-significant fall in systolic and diastolic 
BP. The regions of the heart that demonstrated the greatest segmental decline in 
myocardial blood flow developed new LV RWMA by the end of dialysis (see Figure 
1.12)68.  
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Figure 1.12: Relative change from baseline of the cardiac output (C) and myocardial blood flow 
(D) during haemodialysis68 
 
 
This study illustrates a pronounced fall in myocardial blood flow that occurs early 
during the dialysis session, unrelated to hypovolaemia and is therefore more likely to be 
due to a sequence of events that follow connection to the extracorporeal circuit. In 
patients commencing continuous renal replacement therapy, blood dialyser membrane 
incompatibility triggers a bradykinin response with resultant early onset hypotension69. 
A similar inflammatory reaction is possible in the conventional HD patients however 
this alone does not explain the predominance of myocardial haemodynamic changes but 
raises suspicion about the integrity of myocardial microcirculation. This study also 
demonstrated that the reversible regional left ventricular dysfunction lasted beyond the 
period of reduced perfusion. This is essence completes the clinical evidence for HD 
induced myocardial stunning in adults. 
 
 
  
46
Consequences of myocardial stunning  
The concept of myocardial stunning was first introduced in patients with ischaemic 
heart disease. Repeated episodes of ischaemia and stunning may lead to cumulative, 
more severe and prolonged stunning70 eventually progressing to the phenomenon of 
‘myocardial functional hibernation’, that is non-infarcted, scar free myocardium with 
fixed systolic dysfunction ranging from hypokinesia (depressed contraction), akinesia 
(no contraction) or dyskinesia (paradoxical contraction)71. The extent and severity of 
LV dysfunction can vary considerably and untreated is predictive of morbidity. If a 
discrete region of the LV is involved the impact on ejection fraction can be minimal, 
however with more global involvement heart failure is inevitable.  
 
Myocardial hibernation is thought to represent a functional adaptation to chronic 
hypoperfusion with cardiac myocytes almost adopting an embryonic phenotype72. There 
is conflicting evidence on whether myocardial blood flow to hibernating myocardium is 
normal72, 73 or reduced74 but what is clear is that the coronary flow reserve is severely 
reduced75. Importantly the chronic LV dysfunction that is typical in hibernating 
myocardium can be reversed with restoration of regional myocardial blood flow76. If 
this fails to occur the hibernating myocardium is highly vulnerable to increases in 
demand or reductions in oxygen supply and subsequent stresses are cumulative. The 
knock on effect is a prolonged period to recovery following revascularisation or 
eventual apoptosis or necrosis and non-viable myocardium (see Figure 1.13). 
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In adults the physiological strain and haemodynamic stress during conventional HD is 
sufficient to cause transient myocardial ischaemia with resultant left ventricular (LV) 
dysfunction. Conventional HD regimens comprise of 3 to 4 dialysis treatments per 
week, every week of the year, therefore the potential for repetitive ischaemic 
myocardial insults is both significant and high. Burton et al have undertaken serial 
echocardiographic assessments of global and regional LV performance in prevalent HD 
patients, twelve months apart. They found a significant reduction in segmental 
shortening fraction SF in those segments that had developed RWMAs at baseline 
(Figure 1.14) with 32% developing a fixed reduction in segmental function. 
 
 
Figure 1.14: Change in segmental shortening fraction (SF) in haemodialysis patients  
followed for 12 months67  
 
 
 
Furthermore patients segments with fixed systolic reduction of >60% showed a 
significant decline in ejection fraction over 12 months both at rest and at peak stress 
during HD. There was no significant reduction in LVEF in patients who did not develop 
fixed reductions in segmental function (Figure 1.15)67. 
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Figure 1.15: Change in ejection fraction (EF) at rest and during HD in patients with a fixed 
reduction in segmental function greater than 60% 67 
 
 
 
Records from the US Renal Data System have shown that HD is an independent risk 
factor for the development of both de novo and recurrent heart failure with a two-year 
mortality after a diagnosis of congestive heart failure as high as 51% 77. The aetiology 
of uraemic heart failure is elusive but evidence implicating HD induced myocardial 
stunning story is emerging. However what remains uncertain is whether children on HD 
are also vulnerable. 
 
 
1.10 Strategies for improving intradialytic morbidity 
1.10.1 Sodium profiling 
Following a sodium load, the mechanisms responsible for preserving plasma tonicity 
will maintain plasma sodium within narrow limits by changing the plasma volume. 
During HD, dialysate sodium generates a crystalloid osmotic pressure and thus 
influences fluid shift between the different body compartments, but it also permeates the 
dialysis membrane and thus has the potential for becoming a sodium load.   
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One of the primary objectives of HD is restoration of sodium and fluid balance.  
Sodium is predominantly cleared by convection with the excess water. Pure UF has 
approximately the same sodium activity as plasma with no net change in patient’s 
plasma sodium concentration. Diffusive sodium transport is proportional to the 
difference in sodium concentration between blood and dialysate compartments. 
Dialysate sodium activity is approximately equal to 97% of the measured sodium 
concentration. Similarly the proportion of plasma sodium ions that are bound to protein 
and other anions, are unavailable for exchange. We can measure the free ionized plasma 
water sodium concentration in the blood by using direct ionometry. Plasma sodium 
activity is further limited by the Donnan effect, whereby negatively charged proteins 
(mainly albumin) produce a small electrical potential difference across the membrane 
(negative on the plasma side) that prevents movement of the positively charged sodium 
ions. Concentration differences between interstitial and plasma also stem from the 
Donnan effect. In the absence of UF, we can approximate the concentration of dialysate 
sodium to achieve isotonic dialysis by correcting the blood sodium measured by direct 
ionometry for a Donnan factor of 0.967.  
 
Hyponatric dialysis causes osmotic fluid shift from the extracellular to intracellular 
compartment, dialysis disequilibrium disorder and intradialytic hypotension. 
Hypernatric dialysis transfers sodium to the patient, causing interstitial oedema, 
interdialytic thirst, increased interdialytic weight gain and the worsening hypertension. 
A therapeutic advantage can be gained by manipulating the dialysate sodium 
concentration throughout dialysis. This is referred to sodium profiling, and typically 
utilizes a sodium concentration that falls in a step, linear or exponential fashion. The 
higher dialysate sodium at the start allows a diffusive sodium influx to counterbalance 
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the rapid decline in plasma osmolarity due to clearance of urea and other small 
molecular weight solutes. Low dialysate sodium at the end aids diffusive clearance of 
the sodium load and minimizes hypertonicity. Compared with a constant dialysate 
sodium bath modelling has been shown to increase stability of intradialytic blood 
volume, and reduce both intradialytic cramps and interdialytic fatigue in adults and 
children78. Outcomes have been better with the linear and step profiles compared with 
exponential. Step profiles are most effective at attenuating post-dialytic hypotension and 
early intradialytic hypotension and linear profiles best reduced cramps and late 
intradialytic hypotension. Sodium profiling is also indicated in the prevention of 
dialysis dysequilibrium with patients reporting a preference to it. However one of the 
major drawbacks of sodium profiling is the risk of a positive sodium balance by the end 
of each HD session.  
  
The challenge therefore with sodium profiling is finding the concentration gradient that 
offers the benefits of cardiovascular stability without exposing the patient to a small but 
repeated sodium load. A net sodium gain of 1mmol/l will result in a 1.3% expansion of 
the extracellular space. Based on concerns of inducing hypervolaemia the emphasis is 
shifting to neutral sodium balance profiles. Protocols of isonatriaemic dialysate are 
similar with time averaged dialysate sodium 2-3mEq/l lower (Donnan effect) than the 
predialysis sodium79. Results indicate benefits comparable to sodium profiling with a 
significant decrease in the interdialytic weight gain and thirst score80.  
 
Currently the decision to manipulate dialysate sodium relies heavily on conflicting adult 
literature and there is no comparison of its benefit over other commonly used strategies 
such as UF profiling in children. 
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1.10.2 UF profiling 
Modifying the UF rate throughout dialysis to allow adequate vascular refilling has the 
potential to increase the UF potential. This is the rationale behind UF profiles. The 
plasma refilling capacity increases proportionately with interstitial volume expansion. 
Decreasing stepwise or linear profiles start with high UF rates at the time of maximal 
tissue hydration, progressively reducing the rate in line with decreasing interstitial 
hydration in the hope of maintaining the crucial balance between fluid removal and 
vascular refilling. Intermittent profiles aim to provide periods of active mobilization of 
interstitial fluid into the vascular space when UF rates are low, thereby making it 
amenable to removal during periods of high UF rates. Donauer et al reported lower 
symptomatic hypotension with the decreasing profiles, but the intermittent profile was 
associated with an increased incidence of symptomatic hypotension and post-dialysis 
fatigue81. The incidence of intradialytic hypotension was highest with UF rates greater 
than 1.5 times the average. Ronco et al  observed hypotension at a rate of 6.7/100 
treatments when the UF rate was 0.3 ml/min/kg increasing to 15.8 at an UF rate of 0.4 
ml/min/kg, 25.6 at a rate of 0.5 ml/min/kg, and 67.4 at a rate of 0.6 ml/min/kg82.  
 
Combining UF profiles with sodium profiles can induce plasma hypertonicity. The 
utilisation of a high UF rate with higher dialysate sodium conditions maximises plasma 
refilling and in adults has been shown to be superior to either sodium or UF profiles 
alone in attenuating intradialytic symptoms and cardiovascular instability. Ebel et al 
compared 3 regimens; i) constant dialysate sodium of 138mmol/l, ii) UF profile of 40% 
of the total UF goal in the first hour, 30% in the second hour, 30% in the subsequent 
90mins and then none in the last 30mins, iii) combined UF profile with a sodium profile 
with a dialysate sodium 10% higher than the pre-dialysis plasma sodium, decreased in 5 
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steps to 138 in the last hour. Both the stand alone UF and sodium profiles showed 
evidence of intracellular fluid shift and intravascular hypovolaemia. The combined 
profiles showed higher refilling rates and net removal of fluid from the interstitium and 
reduced renin, aldosterone, epinephrine and norepinephrine levels83, perhaps reflecting 
less marked hypovolaemia and improved vascular stability. Paediatric data on the use of 
UF profiles in isolation or in combination with sodium profiles is non-existent and thus 
efficacy large extrapolated from adult data. 
 
1.10.3 Biofeedback 
The kidneys’ unique ability to maintain homeostasis is achieved by continuously 
adjusting purification in response to transfer of information through a complex system 
of sensing and feedback mechanisms. Until now we have been unable to simulate this 
because traditional HD prescriptions are based on information from previous 
observations. Recently introduced biofeedback systems adjust the treatment prescription 
based on real-time repeated observations from an on-line monitoring system using a 
negative feedback system designed to return the deviating factor to a pre-set nominal 
value.    
 
Blood volume controlled feedback systems respond to RBV changes84. At the start of 
therapy the treatment duration, UF goal, and a target for a maximum decline in BV is 
set. The feedback programme will then adjust the UF rate and (when using the 
Hemocontrol module) dialysate conductivity to maintain RBV along this pre-set target 
thus improving RBV preservation with a more physiological reduction in the RBV 
profile85, 86. Initial results report a reduced incidence of intra-dialytic hypotensive 
episodes and attenuation of post dialysis symptoms87 with a partial response in 
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hypotension prone patients84, 88. Again data in paediatrics is non-existent, nevertheless 
RBV driven UF algorithms have been used in children with success with reports of 
reduce antihypertensive medication burden and UF associated symptoms89.  
 
1.10.4 Sequential dialysis 
Owing to anecdotal experience iso-osmotic fluid removal during sequential dialysis 
techniques (pure UF followed by dialysis) is often used to achieve higher UF rates 
without inducing hemodynamic instability but what remains unclear is how this 
improvement in cardiovascular stability is achieved and the extent of the benefit. 
Isolated UF can be performed by placing the HD machine in bypass or on the UF mode. 
As the patient is no longer being warmed by the dialysate their core temperature drops. 
Traditional thinking believed this to be problematic as patients developed symptoms 
related to cold. In light of emerging evidence the reverse is now believed to be true.  
Cooling over the extracorporeal circuit counteracts the heat generated during dialysis 
and thus prevents an increase in core temperature, peripheral vasodilatation and 
hypotension. Others have postulated that the improved hemodynamic stability is 
secondary to decreased sodium clearance90, 91. Based on personal experiences there is no 
doubt that sequential dialysis can be useful in meeting UF targets during paediatric HD 
but quantitative, comparative data has never been reported.  
 
1.10.5 Intradialytic mannitol  
Dialysis discomfort and dysequilibrium due to cellular osmotic distress occurs as a 
result of changes in osmolarity inducing water shifts from the extracellular to the 
intracellular compartment across the highly permeable blood brain membrane. It was 
first described in 1962 and manifests during or immediately after HD as a self limiting 
  
55
entity but recovery can take several days. Symptoms typically include nausea, vomiting, 
headache, blurred vision, hypertension, seizures and coma but others such as muscular 
cramps, anorexia, restlessness and dizziness have been reported.   
 
The exact pathophysiology of DDS remains unclear and two mechanisms have been 
proposed.  The first, the reverse urea effect, believes that urea clearance from plasma 
occurs more rapidly than brain tissue. This results in a transient osmotic gradient and 
net movement of water from plasma to brain causing cerebral oedema and occasionally 
due to loss of extracellular water, hypotension. The second theory relates to 
intracerebral acidosis and emerged from evidence pertaining to a paradoxical acidaemia 
of CSF and cerebral cortical grey matter in patients and animals treated with rapid HD. 
This is accompanied by increased brain osmole activity due to displacement of sodium 
and potassium ions and enhanced organic acid production. The increased intracellular 
osmolarity induces fluid shifts with subsequent cytotoxic oedema. Both mechanisms 
allude to rapid changes in brain volume. This in turn is thought to damage the blood 
brain barrier and disrupt cerebral autoregulation. Patients identified as high risk of 
developing DDS are new patients, those with a high pre-dialysis urea or high UF goal, 
children and patients with co-morbidites such as pre-existing neurological disease, 
hyponatraemia, malignant hypertension and hypoglycaemia. 
 
Treatment options are both preventative and therapeutic.  The dialysis prescription can 
be adjusted to reduce the rate of plasma urea clearance by downgrading the surface area 
of the dialyser; decreasing the blood flow rate; minimized intradialytic fluid shifts with 
sodium profiles or higher dialysate sodium concentrations and if the patient is grossly 
fluid overloaded to treat using sequential HD with a initial period of UF alone followed 
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by conventional dialysis. In paediatrics mannitol is used almost exclusively as a 
preventative and therapeutic agent. It is osmotically active solute, and can therefore 
artificially increase plasma osmolarity at the time of rapid urea clearance. 
Therapeutically it rapidly lowers intracranial hypertension within minutes of 
administration, with a maximal effect at 20-40mins. Mannitol accumulates in renal 
failure (half-life: 36hrs) and therefore a maximal intradialytic dose of 1g/kg is 
recommended.   
 
One of the greatest challenges relating to DDS resides in the fact that the diagnosis is 
essentially one of exclusion, the main differential diagnosis being intravascular fluid 
depletion. In practice DDS is only treated when symptoms are typical and/or severe and 
therefore the true incidence in children is unknown. Similar to sequential dialysis the 
value of intradialytic mannitol in children has never been quantified, especially within 
the context of modifying the UF potential. 
 
1.10.6 Cooling 
By modifying skin blood flow we can control heat exchange between the body and the 
environment.  This is mediated by two sympathetic nervous systems, an adrenergic 
vasoconstrictor and a less well understood sympathetic vasodilator. During times of 
increased body core temperature, tonic sympathetic vasoconstriction is relaxed and 
active vasodilatation is initiated92 and with heat stress the skin blood flow rate can 
increase from a baseline of 200-500mls/min (5-10% of the total body cardiac output) to 
8l/min (approximately 60% of cardiac output)93, 94. 
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Traditionally dialysate temperatures have been set around 37°C based on presumed 
physiological normal values and to compensate for losses of heat in the extracorporeal 
circuit.  Both of these assumptions have in fact been found to be untrue. In a study of 
HD patients 62.5% of 128 HD adult patients had pre-dialysis body temp below 36.5, 
with marked inter- and intra-individual differences95. There is growing evidence in both 
in adults and children of a net gain and not loss of heat during dialysis speculated to 
have a multifactorial aetiology. Firstly transfer of heat to patients from the warmer 
dialysate. As a result of a higher resting energy expenditure in HD patients compared to 
the normal population, especially in those with residual renal function96. Thermogenesis 
as direct consequence of the inflammatory response invoked when blood comes in 
contact with bioincompatible dialysis membranes. Finally UF activates increased 
sympathetic vasoconstriction, reducing skin blood flow and therefore heat exchange, 
demonstrated by a direct correlation between UF volume and net heat gain97. If the 
accumulation of heat causes an increase in the body core temperature, UF induced 
vasoconstriction is overridden by active vasodilatation.  Blood is redistributed to the 
skin98, the peripheral vascular resistance falls, causing decreased cardiac refilling and 
hypotension99. Fine and Penner95 showed that dialysis patients with subnormal body 
temperature (below 36°C) dialyzed against a 37°C dialysate had a 15.9% incidence of 
symptomatic hypotensive episodes, which fell to 3.4% with 35°C dialysate. Selby et al 
reported an improvement in the degree and severity of HD induced myocardial stunning 
in patients treated with cooled dialysate100. This hemodynamic advantage of “cool” HD 
comes at a price with symptoms related to feeling cold and a theoretical risk of 
adversely affecting urea clearance as a result of compartmental dysequilibrium.  The 
application of ‘cooling’ can complex using a feedback control circuit or simple through 
the manipulation of the dialysate temperature based on the patient’s pre-dialysis 
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temperature. In adults cooling has been associated with improved cardiovascular 
stability and reduced HD induced LV dysfunction100.  
 
1.10.7 Quotidian haemodialysis 
Conversion to frequent HD has been shown to reduce intra- and interdialytic 
hemodynamic instability. This may simply be the result of gentler and more gradual 
fluid. However, there is growing evidence indicating an improvement in a number of 
uraemic cardiovascular co-morbidities in association with superior toxin clearance. 
Quotidian dialysis improves EPO responsiveness and dialysis related inflammation37; 
hypertension and LVH101, 102; conduit artery stiffness and total peripheral resistance; 
endothelium-dependent vasodilatation102; and baroreflex regulation of heart rate103.  
 
Almost exclusively the reported literature features adult studies and paediatric data is 
almost exclusively gained from case series reports. In spite of this the collective 
experience has been positive with improved UF potential and dialysis quality and a 
reduction in intradialytic symptoms. One feature that is relevant in light of the work of 
this MD is that children converting to frequent, 8-10 hour dialysis treatments develop 
chronic asymptomatic pre- and post-dialysis hypotension104. Again owing to a paucity 
of data we do not know whether this has serious implications in the short-term or in the 
future.   
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Chapter Two 
Hypotheses 
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Nature of the Studies 
Cardiovascular disease is prevalent and the most common cause of mortality in children 
with ESRD. Intradialytic hypotension is prevalent and in adults is a known risk factor 
for death. This raises a very valid question, are the two linked? The evidence for the 
cardiovascular burden of HD is growing stronger and with it the urgency for change in 
the way we dialyse our patients. The difficulty in paediatrics is the paucity of data to 
direct us. Studies examining the cardiovascular response to dialysis have been in adults 
and extrapolated to children. There is anecdotal evidence of haemodialysis induced 
haemodynamic disturbance and decompensation in children but the risk has not been 
quantified. Young adults have a constellation of ischaemia predisposing factors 
including increased intima media thickness and pulse wave velocity, coronary artery 
and valvular calcification, endothelial dysfunction and early atherosclerosis. It is 
therefore plausible that children may also display a similar pathophysiology of dialysis 
induced cardiac injury as adults.  
 
Objectives 
The objectives of this thesis are as follows: 
 To determine the prevalence of intradialytic hypotension during conventional 
paediatric HD treatments. 
 To investigate the haemodynamic response to HD in children 
 To ascertain whether changes in intravascular volume are predictive of 
intradialytic hypotension during paediatric HD 
 To investigate global and segmental myocardial function during conventional 
paediatric HD treatments 
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 To determine the efficacy of sodium and UF profiles, sequential dialysis and 
intradialytic mannitol in attenuating intradialytic symptoms and hypotension. 
 
 
Original Hypotheses 
 The aetiology of intradialytic hypotension in children is due to variations in the 
compensatory haemodynamic response to intravascular volume changes during 
dialysis. The aetiology is multifactorial and not exclusively due to UF induced 
hypovolaemia. 
 
 Children with ESRD have developed significant cardiovascular disease that 
predisposes them to ischaemic injury. Conventional HD constitutes a significant 
haemodynamic stress and as such is a procedure associated with a high 
metabolic demand. In the presence of repeated episodes of intradialytic 
hypotension the resultant demand supply mismatch causes ischaemic myocardial 
injury and LV dysfunction. 
 
 Through a better understanding of the mechanism involved in intradialytic 
hypotension the dialysis prescription can be modified to improve cardiovascular 
stability and intradialytic morbidity. 
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Chapter Three 
Haemodynamic Response to Paediatric Haemodialysis  
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3.1 Hypotheses 
 UF is associated with intravascular fluid depletion. 
 Intravascular hypovolaemia induces a compensatory cardiovascular response to 
maintain and support adequate circulation for vital organs. During paediatric HD 
the dominant response varies between patients. 
 Decompensation is prevented by mounting a tachycardia response, increasing 
cardiac contractility and stroke volume (SV) while the total peripheral resistance 
(TPR) rises to sustain central BP.  
 Intradialytic hypotension occurs when theses compensatory mechanisms fail 
combined with changes in intravascular volume. 
 Temporal changes in relative blood volume (RBV) are not able to predict the 
development of intradialytic symptoms and hypotension in children but 
thresholds can help to discriminate between successful treatments and in those in 
which an adverse event occurs.  
 
 
3.2 Introduction  
Adults with ESRD have an altered and abnormal hemodynamic stress response12, 105, 106 
and we assume the same to be true in children. In spite of this, with a desired objective 
of maintaining euvolemia we attempt to remove large volumes of fluid during 
conventional 4 hour HD treatments. In paediatrics, UF volumes of up to 6% of the dry 
weight are prescribed and achieved but at the expense of inducing intradialytic 
symptoms and hypotension. The aetiology of intradiayltic hypotension is complex and 
thought to be caused in part by an impaired cardiovascular compensatory response to 
fluid removal, although the precise mechanisms are still not entirely understood. Plasma 
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refilling is thought to be an important mediator and an imbalance between UF and 
plasma refilling rates will eventually lead to hypovolaemia.   
 
The introduction of non-invasive blood volume monitors (NIVM) has now made it 
possible to measure the relative changes in the blood volume real-time and repeatedly 
during individual dialysis treatments. In addition it has been suggested that RBV 
parameters may predict the occurrence of adverse intradialytic events. In adults a 
critical level of RBV reduction46, gradient of the RBV curve or switching from an 
exponential to a linear RBV reduction have demonstrated predictive ability for the 
occurrence of intradialytic hypotension46, 48. In children RBV literature is dominated by 
studies reporting on the merits of RBV algorithms in guiding UF43, 89  but the predictive 
and discriminating ability of RBV parameters have not been investigated.    
 
 
3.3 Subjects & Methods 
3.3.1  Non-invasive continuous haemodynamic monitoring 
Technique 
The finometer (Finapres Medical Systems, Arnhem, The Netherlands) is a tool designed 
for measuring BP and haemodynamic variables non-invasively, using continuous pulse-
wave analysis at the digital artery (Figure 3.1). Finger arterial pressure is measured 
using the finger-clamp method whereby changes in digital arterial diameter are detected 
by infrared photoplethysmograph107 and opposed by an ultra-fast pressure servo 
controller that changes pressure in an inflatable air bladder, both mounted in a finger 
cuff. This generates an arterial waveform on a beat-to-beat basis form which is then 
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used to reconstruct a central aortic flow waveform108 and calculate a number of 
haemodynamic variables on a continuous basis (see Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Non-invasive continuous haemodynamic monitoring with the finometer 
 
 
Using a nonlinear, self-adaptive, three-element Windkessel model of aortic input 
impedance an algorithm computes the aortic flow waveform from an arterial blood 
pressure pulsation. Zo is characteristic impedance of the proximal aorta; Cw 
'Windkessel' the compliance of the arterial system; and Rp, total systemic peripheral 
resistance. The input is P(t), the arterial pressure waveform and output Q(t) blood flow 
as a function of time. 
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Figure 3.2: Modelling flow from measurements of arterial pressure.  
Left panel: input- the non-invasive pressure for one heartbeat.  
Middle panel: three-element model of aortic input impedance that is used to compute flow from 
pressure Right panel: output- aortic flow as a function of time 
 
 
 
An arm cuff is wrapped around the same arm as the finger cuff to undertake a “Return-
to-flow” calibration109. When arm cuff pressure is supra-systolic, no pulsations can be 
sensed in the finger. The first slight pulsation signals return to flow and is sensed in the 
finger and detected by the software. The finger cuff pressure is read at that instant and 
calibrated against brachial readings. The Finometer has been validated against invasive 
haemodynamic measurements in both children and adults110-114 and shown to be 
accurate, reliable and reproducible.   
 
Patients & Method 
I prospectively selected all chronic HD patients treated at Great Ormond Street Hospital 
for Children, excluding those with overt cardiac disease. Ethics approval for this study 
was granted by the local research ethics board and informed consent was obtained from 
patients or their guardians. 
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The children aged from 11 to 17 years, had been dialysis dependent for 4-130 months. 
The net UF volume ranged from 5 to 61mls/kg. Using the finometer I measured the 
heart rate (HR), blood pressure (BP), stroke volume (SV), cardiac output (CO) and 
peripheral resistance (TPR) for the duration of the dialysis session. All the data was 
downloaded to a PC based analysis program to calculate average results over 5 minute 
time intervals.  
 
Dialysis Prescription 
All patients were dialysed using Gambro AK 95® or Gambro AK100® dialysis 
monitors. Patients received HD for 4 hours, 3 times per week. All dialysis membranes 
were high flux polysulfone or triacetate cellulose membranes, sized to match each 
patient’s body surface area. For all treatments, dialysate contained sodium 140 mmol/l, 
potassium 2mmol/l, calcium 1.75mmol/l, magnesium 0.5mmol/l, bicarbonate 34mmol/l 
with a small quantity of acetate in the acidic component to stabilise the dialysate. The 
dialysate solute concentrations were not formally analysed and verified but assumed to 
be correct based on the from the manufacturers labels. The dialysate temperatures were 
set at constant value of 37.0°C. Dialysate flow rates were maintained at 500mls/min and 
the blood pump speed varied between 80mls/min to 400mls/min depending on the 
patients’ size.  
 
3.3.2 Non-invasive blood volume monitor 
Patients 
I included all children who had undergone at least one month of HD within the dialysis 
unit at the Hospital for Sick Children, Toronto, excluding those receiving total 
parenteral nutrition or blood products (albumin, fresh frozen plasma, blood, platelets) 
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during their treatment and those who were acutely unwell. Patients were subdivided into 
2 groups for the presence or absence of ‘polyuria’, which was defined as a daily urine 
output >1.5mls/kg/hr. Ethics approval for this study was granted by the local research 
ethics board and informed consent was obtained from patients or their guardians. 
 
Baseline characteristics of the patients and dialytic treatments are listed in Table 3.1. 
The underlying renal disease was focal segmental glomerulosclerosis (FSGS)[1 patient], 
autosomal recessive polycystic kidney disease (ARPKD)[1 patient], renal dysplasia [4 
patients], chronic allograft nephropathy and BK virus nephropathy secondary following 
a cardiac transplant[1 patient], membranous glomerulonephritis [1 patient], anti-
neutrophil cytoplasmic antibodies (ANCA) negative glomerulonephritis [1 patient], 
unknown underlying aetiology [2 patients]. Of the 11 patients 5 were polyuric, one 
patient with panhypopituitarism was prone to hypotensive episodes, 1 patient had a 
chronic history of intradialytic cramping and 1 patient had been treated with a second 
heart transplant and had evidence of significant right ventricular dilatation on a peak 
dobutamine stress test but normal LV function at rest. 3 patients had LVH and 5 were 
hypertensive.   
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Table 3.1: Baseline characteristics of patients and their dialytic treatments 
 
Sex (M/F) 6/5 
Age (years) 12.8 [7 to 17] 
Dry weight (kg) 40.2 [18.5 to 69.4] 
Urine output (yes/no) 7/4 
Urine output (mls/kg/hr) 1.61 [0.2 to 2.9] 
Pre-dialysis plasma hemoglobin (g/l) 94.8 [114 to 84] 
Pre-dialysis plasma albumin (g/l) 35.8 [26.5 to 44] 
Pre-dialysis plasma ionized calcium (mmol/l) 1.24 [1.09 to 1.55] 
Mean gross UF (mls/session) 
          UF range in non-polyuric patients  
          UF range in polyuric patients 
1475 [500 to 3500] 
   [1123 to 3500] 
    [408 to 1600] 
Blood flow rate (mls/min) 120-350 
Dialysate flow rate (mls/min) 200-650 
Kt/V 1.71[1.36 to 2.14] 
Mean Systolic BP at the start of dialysis (mmHg) 113 [84 to 170] 
Mean Diastolic BP at the start of dialysis (mmHg) 68.1 [49 to 95] 
Mean Heart rate at the start of dialysis (beats/min) 100 [64 to 133] 
 
 
Dialysis Prescription 
All patients were dialysed using the Fresenius 2008K® or 2008H® for 3hrs, 4 times per 
week or for 4hrs, 3 times per week. In addition if patients arrived for their treatment 
grossly fluid overloaded and remained at least 1kg above their estimated dry weight (or 
0.5kg in a hypotensive prone patient) at the end of dialysis, they returned the following 
day for an additional 2 hr treatment. All dialysis membranes were high flux, triacetate 
cellulose or polysulfone membranes. Dialysis flow rates varied between 200 to 
650mls/min and blood flow rates were calculated to provide a urea clearance of 3 to 
5mls/kg/min. All patients received unfractionated heparin as standard anticoagulation. 
A bolus dose of 15-20u/kg was administered at the start of dialysis followed by a 
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continuous infusion of 15-20u/kg/hr, stopping the heparin infusion over the last 30 
minutes of dialysis. The rate of infusion was adjusted to maintain the activated clotting 
time (ACT) at 20-50% above baseline, with a maximum ACT of 220 seconds. If 
patients were considered to be at a high risk of bleeding no heparin was given. Patients 
were dialysed against 35mmol/l bicarbonate and 1.25mmol/l calcium dialysate solutions 
with a small quantity of acetate in the acidic component to stabilise the dialysate. The 
dialysis water quality was tested monthly and met national standards. The dialysate 
temperatures were set at constant value of 37.5˚C.  Patients were permitted to consume 
one meal during their treatments.   
 
All patients were dialysed with either step or linear, decreasing sodium profiles, starting 
with a sodium concentration of 148mmol/l that dropped to a final concentration of 138 
or 135mmol/l. This was combined with UF profiles (see Figure 3.3): 
- constant UF rate profile [UF profile 0] 
- decreasing step wise decline profile [UF profile 3] 
- decreasing linear decline profile [UF profile 2]  
- high UF rates interspersed between low rates [UF profile 6] 
The maximum UF rate for any profile did not exceed 1.5 times the average rate. The 
dialysis prescription was adjusted monthly to achieve a urea reduction rate between 65 
to 80% and an estimated Kt/V between 1.2 and 1.6115.   
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Figure 3.3: UF profiles 
 
Study Protocol 
During a mid-week or end of the week dialysis session RBV changes were measured 
using the Blood Volume Monitor® (BVM, Fresenius AG, Bad Homburg, Germany). 
Data was recorded hourly throughout treatment, at the time of an ‘adverse event’ prior 
to any nursing intervention and upon recovery. Concurrently, the patient’s heart rate and 
BP, and gross UF volume were recorded. A single BP reading was taken in a sitting 
position using an automated Dinamapp machine with a cuff adjusted for size. An 
‘adverse event’ was defined as an intradialytic event that resulted in a nursing 
intervention (saline bolus, stopping UF, placing the patient in the Trendelenburg 
position, arrest call). Treatment failure was defined as the occurrence of an intradialytic 
adverse event and/or the development of hypotension defined as the first Task Force 5th 
percentile systolic BP measurements8. An exception was made for a hypotension prone 
patient with panhypopituitarism patient in whom the cut-off systolic BP was set at 
75mmHg. Finally the dry weight was assessed monthly from a clinical assessment of 
the patient’s volume status combined with a review of post-dialysis weights at which 
the patient displayed no symptoms indicative of underhydration. If any degree of 
uncertainty remained the size of the cardiac silhouette and on a posterior-anterior view, 
post dialysis chest X-Ray. 
  
72
Statistical analyses 
All values of continuous variables were presented as mean ± standard error. A paired t 
test was used to determine whether there were significant differences between 
continuous variables at the 95th confidence interval (CI), corrected for multiple 
comparisons using Bonferroni. In order to assess the ability of RBV changes to 
discriminate between successful and failed treatments receiver operating characteristics 
(ROC) curves were constructed: 
 actual RBV measurement at the end of the first hour and treatment failure in the 
first or second hour of dialysis 
 actual RBV measurement at the end of the second hour and treatment failure in 
the second or third hour of dialysis 
 hourly RBV difference during the second hour and treatment failure in the 
second or third hour of dialysis.  For example if the RBV was 90% at the start 
and 80% at the end of the second hour, the hourly RBV difference would be 
10%. 
 actual RBV measurement at the end of the third and treatment failure in the third 
or fourth hour of dialysis 
 hourly difference in RBV during the third hour and treatment failure in the third 
or fourth hour of dialysis  
 actual RBV measurement at the end of the fourth hour and treatment failure in 
the fourth hour of dialysis 
 hourly difference in RBV during the fourth hour and treatment failure in the 
fourth hour of dialysis 
 final RBV measurement at the end of dialysis and treatment failure  
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In the evaluation of actual RBV measurements, the ROCs were constructed taking low 
values to be ‘positive’ for treatment failure. For example, using a test threshold of 88%, 
the test is positive for a RBV of 88% or below and negative if the RBV is greater than 
88%. In the analyses of hourly differences in RBV as the discriminator, high values 
were taken to be ‘positive’ for treatment failure. For example, with a test threshold of 
10%, the test is positive if the hourly difference in RBV is greater or equal to 10% and 
negative if the hourly difference is less than 10%. Polyuric patients were excluded from 
the ROC analyses. 
 
A repeated measures ANOVA was used to determine whether the rate of RBV change 
over time or the shape of the RBV curve differed between successful and failed 
treatments, testing for polyuria as a confounder. Measured RBV data from 60 minutes 
to the end of dialysis was entered into the analysis. Finally a logistic regression analysis, 
again with polyuria as a confounder, was conducted to test the relationship between 
treatment outcome (successful or failed treatment) and the predictors: i) final RBV 
measurement at the end of treatment; ii) difference in systolic BP from the start to the 
end of treatment; iii) difference in diastolic BP from the start to the end of treatment; 
and iv) difference between final and initial heart rate.  For all four analyses ‘end of 
treatment’ was defined as the time of completing the prescribed dialysis treatment or the 
time at which an adverse intradialytic event occurred.   
 
All statistical tests were performed using the SAS statistical package (SAS 9.1, North 
Carolina, USA). All statistical tests were two tailed with a p-value less than or equal to 
0.05 taken to indicate significance. The internal correlation of observations from the 
same patients was taken into account by completing repeated measures analyses for all. 
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3.4 Results 
From the 11 patients, 74 RBV curves were recorded of which 15 records were from 
polyuric patients. I have no information on the number of dialysis treatments and thus 
the number of RBV curves that were generated by each patient as I was blinded to the 
selection of patients for RBV analyses. Intradialytic hypotension occurred in 34% 
(26/74) of treatments, associated with RBV changes of up to 30%. Intradialytic 
symptoms occurred in 41% (30/74) of the treatments, 14% (10/74) were stopped 
prematurely and only 53% (39/74) of UF targets could match the volume of the 
intradialytic weight gain.  
 
The hemodynamic response during HD differed between patients and is best 
demonstrated using specific examples. 
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Figure 3.4: Intradialytic haemodynamic response for Patient 1 
 
 
Patient 1 mounted a tachycardic response from the second hour of dialysis. She 
demonstrated a slow gradual decline in her SV and CO during the first 3 hours of 
dialysis with a sudden fall in both in the last hour of dialysis, associated with a drop in 
her BP. Her BP essentially mimicked the TPR and as her TPR became unstable in the 
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3rd and 4th hour her BP followed suit.  Within the group this was a common feature. The 
systolic BP appeared to be most influenced by the TPR and thus if the rise in vascular 
resistance was inadequate, a declining BP followed.                
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Figure 3.5: Intradialytic haemodynamic response for Patient 2  
 
Patient 2 was haemodynamically stable for the first 2 hours of dialysis and then 
suddenly dropped his CO. This was preceded by a short-lived tachycardic response and 
followed by a fall in SV. The BP remained relatively stable up to this point and in fact 
increased at the same time as the patient became tachycardic.  As the heart rate fell so 
did the SV and BP. The BP then stabilized as the TPR increased. Within the group the 
drop in CO was greatest featured in patients that failed to mount an adequate 
tachycardic response. 
 
  
76
0
50
100
150
200
systolic BPHR SV
Time on dialysis (mins) 0 60 120 180
1
2
3
4
5
COTPR
Time on dialysis (mins)
 
 
Figure 3.6: Intradialytic haemodynamic response for Patient 3 
 
 
Patient 3 was a 13 year old with FSGS, oliguria, significant proteinuria and relative 
hypoalbuminaemia. She demonstrated a rising CO and SV during the 2nd hr of dialysis 
presumably due to refilling from the interstitial space. In spite of this, a delayed 
response in TPR resulted in a falling BP. The BP recovered as the TPR increased, in 
parallel with a rising CO. Please note in Patient 3 we were only able to capture data for 
the first 3 hours of dialysis as she did not tolerate the finometer.  
 
The limited number of paediatric specific finger cuffs placed an age restriction of 11 
years old, under which it was not possible to successfully collect data.  Previous studies 
on neonates have reported success on using larger finger cuffs over the patients’ wrists, 
however this method was also unsuccessful. The other major concern with the finometer 
was the fact that it was not tolerated by the children for long periods of time and it was 
only after a lot of cajoling and repeated efforts in some patients that I was able to 
complete the study.  
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The combined group trend, as illustrated below, showed a falling CO and SV and rising 
HR with time on dialysis.  As the systolic BP fell in the latter half of dialysis the TPR 
increased.  As a general rule hypotension was the result of a falling cardiac output (CO) 
combined with an insufficient rise in total peripheral resistance (TPR).                  
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Figure 3.7: Graphical representation of the combined group trend 
 
 
RBV as a Predictor of Outcome 
Regression analysis demonstrated a significant association between change in systolic 
BP during a HD session and final RBV measurement (p=0.05), excluding data from 
polyuric patients (see Figure 3.8).  
 
The presence of polyuria as a confounder had a highly significant effect on the final 
RBV reduction (p<0.0001), such that polyuric patients had higher final RBV 
measurements at the end of dialysis in both successful and failed treatments. 
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Figure 3.8: Graph of absolute final RBV reduction and intradialytic BP change 
 
Multivariate logistic regression was used to test potential predictors of treatment failure 
(Table 3.2). The only variable significantly related to treatment failure was the 
difference in heart rate and the presence of polyuria as a confounder was not statistically 
significant. For each beat per minute increase in heart rate during dialysis there was a 
5% increased risk of treatment failure (p=0.05). 
 
Table 3.2: Logistic regression of complication free treatments in multivariate analysis 
Group p value Odds 
ratio 
95% Confidence 
Interval 
Final RBV measurement at the end of dialysis 
(for each 1% increase) 
0.27 0.95 0.88 – 1.04 
Difference in systolic BP from the start to the 
end of dialysis (for each mmHg decrease) 
0.11 0.97 0.926 – 1.01 
Difference in diastolic BP from the start to the 
end of dialysis (for each mmHg decrease) 
0.47 1.02 0.97 – 1.07 
Difference between final and initial heart rate 
(for each beat/min increase) 
0.05 0.95 0.92 – 0.99 
 
R
2
= 0.57 
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The repeated measures ANOVA found no statistically significant difference in the rates 
of change of the RBV from 1 hour to the end of treatment between successful and failed 
treatments (Figure 3.9).  
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Figure 3.9: Individual RBV curves with group trends for treatments with and without 
complications 
 
The cumulative data in the fourth hour was small and disproportionate, there was one 
treatment failure and 7 seven successful ones. To account for this bias we analyzed the 
data up to the end of the third hour and the fourth hour, but as the results were the same 
we have only reported on the analysis to the end of the third hour. The average RBV 
measurements were higher in the successful treatments but the shape of the RBV curve 
and the rate of RBV change from 1 hour to end of the third hour was not statistically 
significant if including all treatments (p= 0.50) and or after excluding treatments from 
polyuric patients (p= 0.75). There was a significant difference in the average RBV 
measurement at the point of entry into the ANOVA analysis, namely the time intercept 
1 hour (see Figure 3.8). This translates to a statistically significant difference in the 
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average RBV measurement at 60 minutes of dialysis. Therefore the rate of RBV change 
during the first hour of dialysis between the successful and failed treatments was 
statistically significant with a steeper decline in the failed treatments (see Table 3.3).  
 
Table 3.3:  Differences in average absolute RBV measurements for treatments with and without 
complications at intradialytic time intercept 1 hour  
 
Repeated Measures ANOVA for dialysis time 
intercept 1hr 
Average 
RBV 
p 
Value 
95% 
Confidence 
Interval 
Including all RBV curves 
Complication free treatments 90.1 0.01 87.95 – 93.35 
Complicated treatments 86.1 0.01 83.96 - 88.21 
 
Excluding treatments from polyuric patients 
Complication free treatments 86.1 0.05 84.07 – 88.22 
Complicated treatments 83.6 0.05 82.05 – 85.07 
 
 
One factor that was present in all the patients that may have influenced RBV change 
was the consumption of food. However it was not possible to test the relationship 
between the timing and the size of meal in the first hour and changes in RBD reduction 
as every patient consumed a meal and in 90% of cases patients tended to snack on foods 
such as crisps before or after their meal.  
 
 
RBV Reduction as a Discriminator of Successful and Failed Treatment 
We found actual RBV measurements at the end of each hour of dialysis to be better 
discriminators of outcome than hourly RBV differences. Using the hourly difference in 
RBV in the first, second, third and fourth hour, and final RBV measurement at the end 
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of treatment, the 95% CI for the ROC area under the curve (AUC) contained 0.5 (Table 
3.4). Thus these tests are redundant as their application would only provide a 50:50 
odds ratio of discriminating between outcomes and were thus excluded from any further 
analyses. ROC curves were only constructed for actual RBV measurements at the end 
of the first, second and third hours of dialysis. The ROC curves for the first hour can be 
seen in Figures 3.10 and 3.11 
 
Table 3.4: Proposed RBV diagnostic tests and the empirical Area Under Curve (AUC) 
analysis of their ROC curves 
 
Diagnostic Test AUC 95% Confidence 
interval  of AUC 
Absolute RBV measurement at the end of the first hour 0.82 0.68 – 0.90 
Absolute RBV measurement at the end of the second hour 0.79 0.62 – 0.89 
Absolute RBV measurement at the end of the third hour 0.72 0.50 – 0.86 
Absolute RBV measurement at the end of the fourth hour 0.50 0.20 – 0.71 
Final absolute RBV measurement at the end of dialysis  0.50 0.34 – 0.63 
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Figure 3.10: Empirical ROC for absolute RBV change at the end of the first hour of HD 
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Figure 3.11: ROC curve of the absolute RBV change at the end of the first hour of HD based on 
the binormal assumption. 
 
The best cut point on these ROC curves represented a RBV cut-off threshold of 88% at 
the end of the first hour, 84% at the end of the second hour and 82% at the end of the 
third hour. The predictive value of these thresholds for determining treatment failure is 
shown in Table 3.5.   
 
Table 3.5: The predictive value of our ROC derived RBV thresholds testing for  
treatment complications  
 
RBV Threshold  Sensitivity Specificity PPV NPV 
88% at the end of the 1st hour of dialysis 63% 89% 86% 69% 
84% at the end of the 2nd hour of dialysis 58% 94% 96% 52% 
82% at the end of the 3rd hour of dialysis 78% 80% 91% 57% 
 
Test ‘Positive’ if less than or equal to RBV threshold 
Test ‘Negative’ if greater than RBV threshold 
 
PPV- positive predictive value, NPV- negative predictive value 
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3.5 Discussion 
The haemodynamic response during a 4 hour conventional HD treatment was different 
and individual to each child. Similarly there was an intra-patient and inter-patient 
variation in RBV profiles confounded by differences between patients with and without 
significant residual renal function. The gradient of the RBV curve in the first hour and 
changes in intradialytic heart rate were the strongest predictors for the occurrence of 
intradialytic adverse events. 
 
The intradialytic blood volume is dependent on several distinct factors, the volume of 
the extracellular space, the dynamic balance between UF and vascular refilling during 
dialysis, vascular tone and the ability to mount an adequate cardiovascular response at 
times of decompensation. During the course of the dialysis session any one of these 
factors could predominate and therefore also be primarily responsible for precipitating 
hypotension. This would also explain the range of critical RBV thresholds that resulted 
in intradialytic morbidity or the variations in the nature of the compensatory response 
within patients. The analyses of the polyuric patients highlighted the relevance of an 
additional factor, the hydration status of a child. One can hypothesise that patients with 
a high urine output have minimal intradialytic volume expansion and their presenting 
weight is almost identical to their euvolaemic target weight. Therefore minor changes in 
the blood volume could result in hypovolaemia at higher RBV thresholds. At the other 
extreme, in fluid overloaded patients a poor correlation exists between changes in body 
weight and plasma volume with an inverse relationship between pre-dialysis BP and 
intradialytic changes in the plasma volume116. Theoretically therefore, chronically fluid 
overloaded patients or those with an over-estimation of their dry weight should be able 
to achieve higher UF volumes without compromising their circulation.  
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The cardiovascular system demonstrates a high degree of intrinsic autoregulation 
dependent on neural, hormonal and local metabolic control all of which are sensitive 
and affected by disease. Uraemia alters the physiological mechanisms involved in 
maintaining arteriolar tone and cardiac output. Tachycardia is an early and universal 
response to all causes of intravascular compromise105 and this remains true during 
paediatric HD. The tachycardic response was important both in predicting intradialytic 
morbidity and supporting the cardiac output. This would suggest that in the presence of 
uraemia the chronotropic response dominated over the ionotropic response. In fact 
recent adult data concurs with this notion. HD induces segmental myocardial 
dysfunction and even in the presence of the significant haemodynamic stress imposed 
by UF the ejection fraction does not rise117. These findings raise the possibility that HD 
negatively affects myocardial contractility not only in adults but perhaps in children too.  
 
Analogous to newborns, patients with ESRD have increased basal level peripheral 
sympathetic nervous system activity118. In newborns this is associated with a relative 
resistance to the effects of catecholamines and thus increases in heart rate achieve little 
gain in cardiac output, and if excessive may even drop the cardiac output. If we apply 
the same physiology to uraemic children one can explain how the tachycardic response 
is useful in predicting adverse events during dialysis but on its own is unable to prevent 
hypotension from occurring. In reality this is all postulation as I have no evidence to 
support whether this is the pathogenesis for the limited compensatory response in 
children on dialysis, nevertheless I present data that is clearly indicative of a change in 
cardiovascular phenotype in uraemic patients.  
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Children with ESRD show evidence of endothelial dysfunction, reduced vessel 
compliance24 and vascular calcification119. Above this baseline risk the very act of 
dialysis is thought to initiate further endothelial dysfunction. Adult HD patients have 
elevated levels of endothelial cells and endothelial microparticles120, reduced 
endothelial progenitor cell function121 with preservation of smooth muscle progenitor 
cells122. This translates to a vascular environment conducive to injury but without the 
capacity to repair, with triggers that are almost certainly multi-directional. Dialysis is 
recognised as a pro-inflammatory procedure but the mechanisms continue to elude us. 
UF with RBV reductions as high as 30% as demonstrated in this study alter blood 
viscosity and shear stress and this can adversely influence endothelial cell survival and 
quiescence. Severe reductions in afterload during dialysis can induce ischaemic 
endothelial cell apoptosis with continued and repeated depletion of the body’s pool of 
endothelial progenitor cells. The resultant endothelial dysfunction represents a 
molecular state of activation and a switch from a quiescent phenotype towards to one 
that is procoagulant, pro-inflammatory and vasoconstrictive. This is clearly counter-
productive and in all likelihood responsible for the maladaptive regulation of vascular 
tone and the increased predisposition to hypotension. During paediatric HD this may be 
especially important as peripheral vascular resistance was in this cohort one of the 
strongest influences on systolic BP. 
 
Similar to findings in adults, the absolute RBV reduction was unable to predict 
intradialytic hypotension. Dasselar et al found a significant difference in RBV change 
measurements by different NIVMs (the Crit-Line, Hemoscan, and BVM) and those 
obtained from laboratory-derived haemoglobin changes123.  This raises a suspicion of an 
inherent flaw within all NIVMs that produces inaccuracies.  RBV is based on the 
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principle of mass conservation and an assumption that the total amount of blood 
constituent in the circulation is constant, with uniform mixing of red blood cells and 
plasma throughout the circulation or that the relative distribution of blood constituents 
over different vascular beds does not change during dialysis. We now know this 
assumption to be incorrect. Whole blood haematocrit is lower than arterial or venous 
haematocrit due to the dynamic reduction in microvascular haematocrit in capillaries 
and venules (Fahraeus effect)15. The difference is expressed as a F-cell ratio and 
approximates 0.91 in the normal population124. During HD, owing to the redistribution 
of the blood from the microcirculation to the central circulation the F-cell ratio increases 
and thus the observed RBV change in theory underestimates the whole body blood 
volume change125. In fact Agarwal et al tested the diagnostic ability of the RBV slope in 
detecting volume excess and volume depletion. They found that the area under the ROC 
curve was 0.71 to predict volume excess and 0.55 to predict volume depletion126 and 
hence RBV curves were superior in discriminating between volume excess than volume 
depletion.  Therefore the RBV curve lacks potential in predicting the critical point in 
intravascular volume reduction and the onset of decompensation and this may in part be 
explained by the delay in detecting real changes.  
 
This study may not have been able to identify a universal absolute RBV threshold that 
predicts intradialytic morbidity but I was able to determine and validate RBV thresholds 
that discriminated between treatments with and without adverse events. Jain et al have 
proposed similar RBV driven UF algorithms and in contrast to my cut-off RBV 
thresholds of 88% at the end of the first hour, 84% at the end of the second hour and 
82% at the end of the third hour, they defined safe UF with a RBV reduction less than 
8% per hour in the first 90 minutes and less than 4 % thereafter43. The reality is that 
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both may in fact be valid and the discrepancy relates to differences in the dialysis 
prescription and choice of NIVM. The Blood Volume Monitor® measures the 
difference in blood density and is dependent on the total protein concentration and the 
Crit-line®, the device used by Jain measures the red blood cell concentration through 
assessment of the optical density of whole blood. There is no doubt that the accuracy of 
readings between the two devices is similar however the RBV measurements are not 
directly interchangeable. Schneditz et al demonstrated a 2% difference in relative blood 
volume changes (BVM 2% less reduction in blood volume compared to Crit-line) that 
developed approximately 1 hr into dialysis, and persisted thereafter41.  The dialysis 
prescription is also relevant to this discussion. Jain studied patients dialysed against a 
fixed dialysate sodium concentration of 140mEq/l and provided no details on UF rates. 
In contrast the objective of this study was to validate RBV thresholds over a range of 
dialysis sodium and UF prescriptions thus making it more broadly applicable clinically. 
The theoretical problem with this approach is that we know that dialysate sodium and 
UF rates influence dialysis quality and risk of intradialytic symptoms and hypotension78, 
127
. In an attempt to address this possible bias I tested the possibility of an independent 
effect of the dialysis prescription on the frequency of adverse events. By entering my 
data into a repeated measures Generalized Estimating Equations model I analysed the 
odds of adverse events between the UF profiles and two sodium profiles and found no 
statistically significant differences between the groups. Thus I present RBV thresholds 
that have the potential to guide safe UF but would recommend against prescriptive 
application of these thresholds as adjustments may be required with local differences in 
dialysis conditions.  
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3.6 Study limitations  
First and foremost my study was performed in a small and heterogenous population. 
However as this was the formal first assessment of this kind in children my initial aim 
was not to be over restrictive on the recruitment process. In the world of paediatric HD 
where single centre patient numbers rarely exceed 20, maintaining such a broad 
inclusion criteria was necessary in order to achieve an adequate and appropriate cohort 
size. Clearly in the converse it also has the potential to introduce bias.  
 
Treatments were not standardized for patient factors such as postural changes during 
dialysis and food intake which are known to influence the accuracy of NIVM and 
cardiovascular dynamics. Similarly sodium and UF profiles, and the use of short 
intervals of isolated UF are all dialysis factors with the potential to influence 
cardiovascular stability during dialysis. The results should therefore be interpreted 
within the limitations of its design. 
 
The numbers were further depleted in the finometer study owing to the restrictions 
imposed by the size limitations of the finger cuffs. The smallest finger cuff size was 
only suitable for children 11 years or over and hence we were unable to get any data on 
6 patients. Previous studies on neonates have reported success on using larger finger 
cuffs over the patient’s wrist, but in my hands this method failed to produce an adequate 
trace and was therefore abandoned. The other major concern with the finometer was the 
fact that it was not tolerated by the children for long periods of time. The cuff had to be 
wrapped tightly around the finger for the finger-clamp method to be effective and the 
longer the cuff remained in place the greater the likelihood of adverse symptoms. 
Children complained of the finger becoming numb, white and cold to touch. The wrist 
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strap that housed all the sensors and adaptors was also relatively heavy and cumbersome 
and this prompted several verbal complaints. The design of the finometer was such that 
it was reported to be able to cope with movements in the arm without having a hegative 
impact on the trace. However this did not match my own experience. Typically a child 
on dialysis would eat lunch, watch TV, play games or was encouraged to do their 
homework. In the children studies the resultant movement from these activities 
frequently resulted in sensor failure and repeated interruptions in the trace.  
 
Clearly a child’s cooperation is paramount to attaining finometer data and on reflection 
I feel that the method used in this study will require change during subsequent studies. 
The objective in dialysis studies is to measure changes in haemodynamic variables with 
time on dialysis. In theory this can also be achieved by attempting finometer traces for 
15-30minute intervals per hour of dialysis. If the first time aliquot starts prior to the 
patient being connected, baseline information will be captured while the final 30 
minutes will capture the period at the end of dialysis and hence the time of peak stress 
in addition to the recovery period during washback and disconnection from the dialysis 
circuit. I am also hoping that by allowing the children respite time, free from the 
finometer, compliance and co-operation may improve.    
 
The other major limitation of this study was the fact that the two arms of the study were 
conducted in different patients. The Hospital for Sick Children, Toronto had already 
invested in NIVMs and hence this study was possible there. In contrast Great Ormond 
Street Hospital had access to the finometer but not NIVMs. This preliminary data has 
been very useful in determining group trends and directing future studies but there is no 
doubt that to accurately assess trends in individual patients simultaneous data from both 
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the finometer and RBV monitoring is required. This would also be more in keeping with 
the future direction of HD treatments, that of individualised treatments.  
 
 
3.7 Conclusion 
In conclusion the hemodynamic response to conventional HD treatments and UF is 
different and individual to each child.  The evolution of tachycardia and the gradient of 
decline of the RBV curve during the first hour of treatment can be useful in predicting 
the occurrence of intradialytic adverse events.  The blood volume profiles from patients 
with significant residual urine output were different from oligo-anuric patients.  
 
Cut-off RBV thresholds of 88% at the end of the first hour, 84% at the end of the 
second hour and 82% at the end of the third hour were the best discriminators of 
outcome with a high specificity and PPV for treatment failure but limited sensitivity and 
NPV. Knowledge of patient specific adaptive responses may allow us to target 
interventions in supporting circulation during subsequent dialysis sessions. 
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Chapter Four 
Myocardial Consequences of Haemodialysis  
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4.1 Hypotheses 
 Uraemic children have a predisposition for demand ischaemia 
 The extracorporeal blood volume necessary for priming the HD circuit 
combined with the intravascular fluid depletion during UF amounts to a 
significant haemodynamic stress. 
 The resultant effect is HD induced cardiac perfusion defects and regional 
myocardial dysfunction  
 Speckle tracking two-dimensional strain is more sensitive in detecting ischaemic 
myocardial dysfunction than assessment of regional wall motion activity. 
 
 
4.2 Introduction 
Cardiovascular mortality is grossly elevated in HD patients. CKD have a 30 fold 
increase in mortality than age-matched controls and an even higher risk of up to 800 
fold for dialysis and young adults20. This excess of cardiovascular death is only partly 
explained by an increase in traditional risk factors, and several mechanisms of cardiac 
damage specific to the uraemic milieu have been identified. It is also becoming 
increasingly apparent that HD in itself confers a risk but the pathophysiological 
mechanisms remain elusive. In adults there is evidence from isotopic65, 
electrocardiographic60, 128, biochemical58, 59 and echocardiographic100, 117 studies 
implicating HD as a source of recurrent subclinical myocardial cell injury, even in the 
absence of pre-existing large vessel epicardial coronary artery disease (CAD). Single 
photon emission computed tomography (PET) adult data has demonstrated acute 
reductions in global and segmental myocardial blood flow during HD, with matched 
reversible reductions in segmental contractile function65, consistent with the definition 
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of myocardial stunning55. The number of stunned segments and the intensity of stunning 
within segments correlate with intradialytic BP changes and UF volume129. In the model 
of CAD, repeated stunning leads to myocardial hibernation with resultant heart failure71. 
Within dialysis patients transient myocardial ischemia precipitates cardiac 
arrhythmias130 and progresses to fixed regional systolic dysfunction and reduced global 
systolic function 67. 
 
Uraemic children and young adults have a similar constellation of ischaemia 
predisposing factors to adults, including increased intima media thickness and pulse 
wave velocity, vascular calcification, early atherosclerosis and endothelial dysfunction 
24, 119
, but without significant atheromatous CAD. In the previous study I have 
demonstrated that the incidence of HD induced haemodynamic disturbance is 
comparable to adults, with a 20-30% incidence of intradialytic hypotension associated 
with a relative blood volume reduction of 20-25%. It is therefore plausible that children 
may also display a similar pathophysiology of dialysis induced cardiac injury as a result 
of characteristic uraemic cardiovascular abnormalities. 
 
Regional wall motion assessment (RWMA) is primarily an assessment in the 
longitudinal axis and uses the inward motion of endocardial borders as the sole marker 
of abnormal contraction. In contrast 2D speckle tracking provides a multi-axis 
assessment of LV function employing functional components that are not visible to the 
naked eye. Speckle tracking strain is also both translation and angle independent with 
lower inter and intra-operator variability compared with RWMA131 in adults. This 
makes it a very promising novel technique for detecting regional LV dysfunction, 
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especially within this context. Uraemic children have no evidence of epicardial coronary 
artery disease and thus the extent of ischaemic injury may be mild and findings subtle.   
 
 
4.3 Method 
4.3.1 Patients 
All patients at Great Ormond Street Hospital that had been on HD for at least one month 
were considered for inclusion within the study. I excluded those patients with congenital 
heart disease, a concurrent respiratory illness or if it was not possible to obtain 
echocardiographic images of sufficient quality to allow meaningful analysis owing to 
poor windows for visualizing the heart.  Ethics approval for this study was granted by 
the local research ethics board and informed consent was obtained from patients or their 
guardians. 
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Table 4.1: Patient Demographics 
 
n/a: not available 
 
AV fistula: arteriovenous fistula 
LV: left ventricle 
 
* Patients recruited for the Regional wall motion Study 
§  Patients recruited for the 2D strain Study 
 
Patient 
Age 
(yrs) 
Time 
on HD 
(mths) 
Cause of ESRD AV fistula 
LV 
septum 
[Z-score] 
LV 
Posterior 
wall 
[Z-score] 
*
§ 1  5 4 Renal dysplasia yes 1.3 1.7 
*
§ 2  17 89 Cystinosis yes 1.6 0.3 
*
§ 3  15 43 Focal segmental  glomerulosclerosis yes 0.1 1.4 
*
§ 4  15 4 Renal dysplasia yes 0.3 0.2 
*
§ 5  15 32 Focal segmental  glomerulosclerosis yes 2.6 1.9 
*
§ 6  13 4 Renal dysplasia no 5.9 6.3 
*
§ 7  11 35 Renal dysplasia yes 0.5 -0.6 
*
§ 8  13 15 Focal segmental  glomerulosclerosis no 0.6 -1.1 
*
§ 9  2 7 Glomerulocystic disease no 1.5 1.7 
* 10  17 12 Reflux nephropathy yes 1.9 1.7 
* 11  7 62 Autosomal recessive polycystic kidney disease yes 1.0 0.3 
*
§ 12  14 6 Cystic dysplasia yes 2.6 1.2 
§ 13 13 2 Focal segmental  glomerulosclerosis no 0.4 03 
§ 14 2 2 Nephronophthisis no 1.2 1.3 
§ 15 1 2 Oxalosis no 0.7 0.8 
§ 16 8 24 Congenital nephrotic 
syndrome no n/a n/a 
§ 17 15 2 Renal dysplasia no 1.4 1.6 
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Of the 17 patients 9 had AV fistulae as their dialysis vascular access and in the 
remainder central tunnelled venous catheters were used. 5 patients had previous failed 
transplants and 2 patients had three months of peritoneal dialysis prior to HD. Residual 
urine output varied amongst the study group, 7 patients were anuric, 5 patients passed 
less than 1ml/kg/hr of urine and 5 patients passed between 1-2 mls/kg/hr. At their 
baseline examinations only one patient had LV hypertrophy and three patients had 
borderline hypertrophy (see Table 4.1 
 
 
4.3.2 Dialysis Prescription 
All patients were dialysed using Gambro 200S® dialysis monitors. Patients received 
HD for 4 hours, 3 times per week. All dialysis membranes were high flux polysulfone 
or triacetate cellulose membranes using sizes that at minimum were equivalent to each 
patient’s body surface area. For all treatments the dialysate contained sodium140 
mmol/l, potassium 2mmol/l, calcium 1.75mmol/l, magnesium 0.5mmol/l, bicarbonate 
34mmol/l with a small quantity of acetate in the acidic component to stabilise the 
dialysate. The dialysate temperature was set at a constant value of 37.0˚C. Dialysate 
flow rates were maintained at 500mls/min and blood pump speeds varied between 
80mls/min to 400mls/min depending on the patients’ size. The dialysis prescription was 
adjusted monthly to achieve a urea reduction ratio greater than 65% and Kt/V urea 
greater than 1.2 (calculated from Daugiradas single pool kinetics)115. All patients 
received unfractionated heparin as required. Patients were permitted to consume one 
meal during their treatment. For each session, net fluid removal was set on an individual 
basis and adjusted to restore the patient to their ideal dry weight (clinically determined) 
by the end of the dialysis session. UF took place in parallel with dialysis using constant 
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UF rates unless patients had higher than normal UF requirements. In these 
circumstances patients received 30 minutes of isolated UF at the beginning and/or the 
end of the HD session. 
 
 
4.3.3 Regional wall motion assessment 
Technique 
Using 2-dimensional (2D) echocardiography standard apical 2-chamber and 4-chamber 
views are taken to visualise the LV endocardial border in 2 planes at 90 degrees to each 
other. These images are then copied onto CDs in DICOM format for off-line analysis 
using a personal computer based digitising programme (Echo-CMS, MEDIS, Leiden, 
The Netherlands)132. Three consecutive heartbeats were analysed for each time point 
(extrasystolic beats were excluded). Endocardial borders (excluding papillary muscles) 
were traced semi-automatically for each videoframe of the 3-beat sequence, and any 
anomalies corrected manually. Maximal displacement of the endocardial border from a 
centre point was then measured over each of 100 chords around the LV wall, corrected 
for end-diastolic LV circumference (see Figure 4.1) and expressed as percentage 
shortening fraction (SF). Each apical view was divided into 5 segments and SF for the 
chords in each segment was averaged so 10 regions of the LV were assessed at each 
time point. Any segmental endocardial border that was not clearly visible was excluded 
from analysis. Segmental reduced regional wall motion (RRWM) was defined as a 
decline in SF of >20% from baseline and degrees of hyperkinesis 20% and 50% were 
defined as those segments that demonstrated a increase in SF of >20% and >50% 
respectively. I calculated the mean SF for all ten segments (SF[Overall]), for those 
segments that developed new RRWM (SF[RRWA]) and those segments that did not 
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develop RRWM (SF[Non-RRWM]). Ejection fraction (EF) was calculated from the apical 
four chamber and 2 chamber view by the Simpson’s rule. The LV posterior and septal 
wall thickness was measured from parasternal long axis M-mode images, and 
represented as Z-scores after adjusting for age and body surface area.  
Figure 4.1: Assessment of regional wall motion activity by Echo CMS.  
On the left panel highlighted in blue is an example of a semi-automatic tracing of the 
endocardial border. On the right panel each red line represents a measurement of the regional 
endocardial border movement.   
 
 
Study Protocol 
For each monitored dialysis treatment, serial echocardiography was performed at the 
start of dialysis (baseline), 2 hours into the dialysis session, the end of the dialysis 
session and at recovery 15mins after dialysis, once a saline wash-back had been given 
and the patients had been disconnected from the machine. Ideally I would have 
preferred a longer period post dialysis prior to re-assess the cardiac function, but owing 
to travel times and other social reasons patients refused. Blood samples were collected 
before and after each session in lithium heparin and EDTA tubes, and biochemical 
  
99
analysis performed on a multichannel autoanalyser for routine electrochemical, full 
blood count and high sensitivity C-reactive protein (hsCRP). Cardiac troponin-I (cTnI) 
analysis was preformed using a chemiluminescent assay on a Beckman Access 
Immunoassay analyser. Pre dialysis blood tests were drawn immediately after insertion 
of access needles or catheter connection, and post levels were taken from the arterial 
line after reducing the blood pump speed to 50ml/min. During each dialysis session the 
net UF volume and intradialytic symptoms with corresponding heart rate and BP 
measurements were recorded. For each patient echocardiography data was collected 
during two separate dialysis sessions, separated by no more than four weeks. The 
primary endpoint of HD induced myocardial stunning was determined from the degree 
of change in LV segmental SF, and the number of segments involved. The secondary 
endpoint was to assess whether a relationship existed between reduced segmental LV 
function and intradialytic BP and UF volume. 
 
Statistical analyses 
The data comprised of 2 data sets of 12 from the same patients. Therefore in order to 
determine the prevalence of myocardial stunning only one data set was used, selected at 
random, by tossing a coin. To test the association between dialysis and patient related 
factors and the severity of stunning I was able to combine the data sets by incorporating 
a repeated measures analysis into the analysis. 
 
The results were expressed as mean ± SD if parametric or the median and interquartile 
range (IQR) if non-parametric. Echocardiographic and haemodynamic data were 
analysed using one-way analysis of variance (ANOVA), with a design for repeated 
measures. Depending on Gaussian distribution, all other data were analysed using either 
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the paired or unpaired t tests or the Mann-Whitney or Wilcoxon matched pair tests. To 
test for the association between both the mean %SF[RRWM] and SF[non-RRWM] at 240 
minutes  against dialysis related factors (UF volume-mls/kg dry weight, intradialytic 
BP) and patients related factors (dialysis vintage, age) I used univariate regression 
analysis adjusting for repeated measures. I did not attempt multivariate logistic 
regression analysis due to the relatively small sample size. In all analyses, an alpha error 
at p<0.05 was judged to be significant. 
 
 
4.3.4 Speckle tracking two-dimensional strain assessment 
Technique 
The speckle tracking strain software analyzes motion by tracking ‘speckles’ from frame 
to frame in 2D echocardiogram images. Speckles are natural acoustic markers of 20-40 
pixels that are equally distributed throughout the myocardium. By following the 
movement of each speckle throughout a single cardiac cycle a temporal assessment of 
myocardial muscle deformation is achieved (see Figure 4.2).  
 
Standard grayscale 2D images were acquired in the 4-chamber apical views and 
parasternal short-axis views at the level of the papillary muscles (the level of mid wall 
contraction) using frame rates of 50 frames per second minimum. The apical images 
were required to assess peak longitudinal strain and the parasternal images for radial 
and circumferential strain. The images were stored digitally in raw format for analysis 
later. From an end-systolic single frame a region of interest was traced on the 
endocardial border by a point-and-click approach. The 2D strain algorithm then 
automatically evaluates the tracking quality at each myocardial region over time and 
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assigns each segment an ‘acceptable’ or non-acceptable’ label. For each image that was 
analysed the region of interest was manually adjusted until all the segments had 
acceptable tracking quality. The specialist software then processed and generated LV 
segmental time-strain curves from which the timing and value of peak strain per 
segment were extracted.  For the purpose of 2D speckle tracking the LV was divided 
into 6 segments as shown in Figure 4.3. 
 
 
Figure 4.2: LV segmentation in the long axis (left) and short axis (right) for the purpose of 
regional strain measurements.  
 
 
Speckle tracking for assessment of cardiac motion and dyssynchrony has been validated 
in adults with intraobserver and interobserver variability of 3.6% to 5.3%131 but the 
experience in children is extremely limited133.  
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Figure 4.3: Two-Dimensional Strain Imaging.  
In the left panels the strain images are represented. The arrows highlights the type of deformation 
assessed in each view: radial thickening (A), circumferential shortening (B), and longitudinal shortening 
(C). The right panel demonstrate the segmental time-strain curves for a synchronous left ventricle AVC 
refers to aortic valve closure and represents the end of systole. [Adapted from Delgado134]. 
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Study Protocol 
For each monitored dialysis treatment, echocardiography was performed at the start of 
dialysis (baseline) and again at the end of the dialysis session, the time of peak stress. 
During each dialysis session intradialytic symptoms with corresponding heart rate and 
BP measurements were recorded in addition to the net UF volume at the end of each 
treatment.  The images were then analysed with specialist 2D speckle tracking software 
to generate segmental longitudinal, radial and circumferential time strain curves. For 
each time point the peak segmental strain was recorded. To test for dyssynchrony two 
parameters were used, i) the maximal time delay between peak strain of 2 segments and 
ii) asynchrony index, which was derived by calculating the standard deviation of time to 
peak strain over the 6 segments. 
 
Finally speckle tracking 2D strain assessments were performed on age matched controls 
at rest using longitudinal and parasternal (papillary muscle level) 2D echocardiographic 
grayscale images.  
 
Statistical analyses 
Echocardiographic and haemodynamic data differences within patients at the start and 
end of HD were analysed using ANOVA, with a design for repeated measures. Pearsons 
correlation analyses were performed to assess the relation between intradialytic strain 
reduction and dialysis related factors (UF volume-mls/kg dry weight, intradialytic BP) 
and patients related factors (dialysis vintage, age). Univariate linear regression analyses 
were used to determine predictors of intradialytic BP change. In all analyses, an alpha 
error at p<0.05 was judged to be significant. 
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4.4 Results 
4.4.1 Regional wall motion assessment 
Global & Segmental Ventricular Function 
The median LVEF was 51.8%, range 38.2 to 68.1 at baseline, 55.7% (44.2 to 66.7) at 
120mins of HD, 53.21% (37.8 to 71.5) at 240mins and 55% (43.5 to 64) on recovery 15 
minutes after dialysis (see Figure 4.4), but the differences between all the time points 
were not statistically significant (p=0.56). At the start of dialysis 4 patients had LVEF 
below the lower limit of normal, namely 50%. 
 
Figure 4.4: Changes in global and segmental LV function during HD 
 
 
* Ejection fraction is represented as mean and standard deviation. The difference at the 4 time points was 
not statistically significant (p=0.56) 
† Mean segmental %SF[Overall] represented as the cohort mean and box plot of the individual results. The 
difference between the baseline and both 120m and 240m was statistically significant (p<0.05) 
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All 12 patients developed segments with RRWM in 1-5 segments (see Figure 4.5), with 
co-existing 20% hyperkinesis in 1-4 non stunned segments in 11/12 patients from 
120mins that persisted into recovery. In addition 9/12 patients exhibited 50% 
hyperkinesis in as many as 3 segments. Again this was evident at 120mins and persisted 
into recovery (see Figure 4.5), Of the 35/120 segments that stunned mid-cavity 
segments dominated followed by basal and then apical segments.  
 
Figure 4.5: Segmental RRWM and hyperkinesis during HD 
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 The resultant effect on segmental shortening fraction was a fall of the mean segmental 
%SF[Overall] from 2.2 ± 0.4 (mean ± standard deviation)  at baseline to 1.9 ± 0.3 by 
120mins, 1.8 ± 0.4 at 240mins with an increase to 2.1 ± 0.5 post dialysis (see Figure 
4.6). The difference was statistically significant when comparing baseline segmental 
%SF[Overall] to that at 120mins and 240mins (p<0.05) but did not reach significance on 
comparing %SF[Overall] at 120mins, 240mins (p=0.34) and at recovery. There was a  
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statistically significant fall in the mean segmental %SF[RRWM] from 2.7 ± 1.1 at baseline, 
1.9 ± 0.7 at 120mins, 1.4  ± 0.6 at 240mins, and 2.2 ± 0.7 at recovery (p<0.05) (see 
Figure 4.7).  
 
Figure 4.6: Differences in mean segmental percentage SF in those developing RRWM 
P<0.05 P=0.17
P=0.38
P<0.05
Baseline 120 mins 240 mins Recovery
0
1
2
3
4
5
6
 
 
Figure 4.7: Mean segmental percentage SF in those developing RRWM 
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10/12 patients showed evidence of resolution of RRWM on recovery, as early as 
15mins after completing dialysis (see Figure 4.8). The mean segmental %SF[nonRRWM]  
increased from baseline to 240mins, 2.0 ± 0.6 to 2.3 ± 0.6 but did not reach statistical 
significance (p=0.07) (see Figure 4.8). The mean segmental %SF in the segments that 
developed RRWM was higher at baseline compared with those that did not (2.35 ± 0.52 
versus 1.98 ±0.63) (see Figure 4.8). 
 
 
Figure 4.8: Mean Segmental Percentage Shortening Fraction Relative to Time On HD 
 
 
 
 
 
 
 
 
 
 
• Significant difference between %SF[Overall] {baseline v 120m} 
•  and {baseline v 240m} (p<0.05) 
 
† Significant difference between %SF[RRWM] {baseline v 120m}, {baseline v 240m}, {120m v 240m} and 
{240m v recovery} (p<0.05) 
‡ In the remaining groups the difference was not statistically significant 
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This pattern of dialysis induced segmental RRWM is consistent with the definition of 
myocardial stunning. Pictorial representation of serial regional wall motion assessment 
from 2 patients illustrates the transient regional myocardial dysfunction that is seen 
during a HD treatment (see Figures 4.9 and 4.10).   
 
Figure 4.9: Serial regional wall motion assessment from Patient 7 during HD 
 
 
 
Figure 4.10: Serial regional wall motion assessment from Patient 9 during HD 
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Factors Associated With The Development Of Myocardial Stunning 
The median intradialytic systolic BP fall for the group was 25 mmHg (range 6-
90mmHg) and the lowest intradialytic systolic dialysis BP ranged from 58 to 
110mmHg. A strong correlation was seen between intradialytic systolic BP change and 
mean segmental %SF[RRWM] (r = 0.56, p<0.05) as shown on figure 4.11. Similarly on 
univariate linear regression analysis there was a significant association between 
intradialytic systolic BP changes and mean segmental %SF[RRWM] (p<0.05), but not 
against lowest intradialytic systolic BP (p=0.68). 
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Figure 4.11: Graph of intradialytic blood pressure change and LV mean segmental shortening 
fraction 
 
The median UF volume for the group was 29.4mls/kg (range 2-94mls/kg), and in one 
patient no UF was attempted. There was no significant association between UF volume 
and the number of segments that developed RRWM, or the mean segmental %SF[RRWM]. 
Likewise on univariate linear regression analysis there was no association between UF 
volumes and mean segmental %SF[RRWM] (p=0.6). When considering both intradialytic 
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BP change and UF against the mean segmental %SF[RRWM] the relationship between 
intradialytic BP change and the mean segmental %SF[RRWM] disappeared (p=0.24). In 
this patient group UF volume correlated with change in BP during HD (r=0.56, p<0.05) 
as shown in Figure 4.12. Similarly on univariate linear regression there was a significant 
association between systolic BP change and UF volume (p<0.05, r2 0.32).     
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Figure 4.12: Graph illustrating the relationship between Systolic BP change and UF volume 
 
I found no significant relationship between the number or intensity of RRWM as 
measured by the mean %SF[RRWM] against patient age, dialysis vintage, pre-dialysis 
plasma urea levels, anaemia, LV mass, hsCRP or cTnI and the presence of a 
arteriovenous fistula. I could not test for the relationship between the absolute or change 
in heart rate during dialysis and RRWM as it was impossible to separate the tachycardic 
response that evolved as part of the haemodynamic response to HD and that as a direct 
result of the children, especially the infants, getting upset and crying during their echo 
assessments.  
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Hematological &Biochemical Profile& Markers of Cardiac Injury  
The biochemical and hematological profile was typical of HD patients, showing a 
prevalence of anaemia (n= 5), hyperparathyroidism (n=7), hyperphosphataemia (n= 5) 
and acidosis (n=4). Routine laboratory values and dialysis adequacy are summarised in 
Table 4.2. Values for hsCRP exceeded 1µg/l in 6 patients post-dialysis and 3µg/l in one 
patient post-dialysis. In 8/12 patients the post-dialysis cardiac troponin I (cTnI) levels 
remained the same as pre-dialysis levels of <0.04µg/l. In the remaining 4 patients the 
cTnI levels increased post dialysis to up to 0.07µg/l (see Table 4.3). 
 
 
Table 4.2: Biochemical and Haematological Profile 
 Mean ± Standard Deviation Range 
Pre-dialysis Urea (mmol/l) 22.5 ± 4.2 15.2 to 28.2 
Post-dialysis Urea (mmol/l) 4.5 ± 1.5 1.5 to 6.9 
KT/V urea 2.0 ± 0.5 0.5 to 3.1 
URR (%) 80 ± 6 72 to 91 
Haemoglobin (g/dl) 11.5 ± 1.4 9.1 to 13.1 
Potassium (mmol/l) 5.3 ± 0.7 3.7 to 6.4 
Phosphate (mmol/l) 1.5 ± 0.6 0.6 to 2.9 
Albumin (g/l) 38.3 ± 2.5 34 to 41 
PTH (pmol/l) 22.4 ± 22.9 0.3 to 89 
Ionised Calcium (mmol/l) 1.2 ± 0.1 1.09 to 1.44 
Bicarbonate (mmol/l) 23.9 ± 2.4 20 to 27 
hs CRP (µg/l 1.9 ± 1.5 0.4 to 5.5 
 
 
URR:  urea reduction rate 
PTH: parathyroid hormone  
hsCRP: highly sensitive C-reactive protein 
  
112
Table 4.3: Cardiac Troponin I levels pre and post dialysis 
Patient Baseline cTNI (µg/l) Post dialysis cTNI (µg/l) 
1 <0.04 0.04 
2 0.05 0.07 
3 <0.04 0.04 
4 <0.04 <0.04 
5 <0.04 <0.04 
6 <0.04 <0.04 
7 <0.04 <0.04 
8 <0.04 0.04 
9 <0.04 <0.04 
10 Not available Not available 
11 <0.04 <0.04 
12 <0.04 <0.04 
 
cTNI: Cardiac Troponin I 
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4.4.2  
Speckle tracking two-dimensional strain assessment 
For each patient speckle tracking 2D strain echo images were acquired during a single 
HD. However during the data analysis and thus assessment of peak strain and 
asynchrony three cardiac cycles were analysed per patient at each time point.  
 
Peak Segmental Strain 
Compared with age matched controls the peak segmental longitudinal strain was lower 
in uraemic patients at the start of dialysis. The difference was statistically significant in 
the baso-septal, mid-septal, mid-lateral and baso-lateral segments. During dialysis the 
peak longitudinal strain fell and the difference was statistically significant in all the 
segments (see Table 4.4). 
 
There was no segmental difference in peak circumferential strain between the controls 
and uraemic patients pre-dialysis. During dialysis the peak circumferential strain fell 
and the difference was statistically significant in the lateral and posterior segments. The 
exception was the antero-septal segments in which the peak circumferential strain was 
significantly higher (see Table 4.5). 
 
Segmental peak radial strain was lower in uraemic children pre-dialysis compared with 
age matched controls. The difference was statistically significant in the anterior, 
posterior, inferior and lateral segments. During dialysis the peak radial strain increased 
in all the segments but the difference only achieved statistical significance in the 
posterior segments (see Table 4.6).   
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Inter-segmental Synchronicity 
The asynchrony index or standard deviation of time to peak strain over the 6 segments 
was significantly higher pre-dialysis compared with the controls and higher still post 
dialysis in all 3 axes.  Similarly the maximum inter-segmental time difference to peak 
strain progressively increased from the age matched controls to uraemic patients pre-
dialysis and higher still in the post dialysis patients. The difference was statistically 
significant in the longitudinal, circumferential and radial axes (see Table 4.4 to 4.6).  
 
Figures 4.13 and 4.14 represent longitudinal time strain curves for patients 7 and 9, the 
same patients whose regional wall motion assessments were shown in Figures 4.9 and 
4.10 earlier in this chapter. The longitudinal strain curves demonstrate a reduction in 
peak longitudinal strain post dialysis and variations in the time to peak strain between 
the 6 segments.  
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Table 4.4: LV segmental longitudinal strain 
 
 Pre-dialysis 
Mean 
[95% CI] 
Post-dialysis 
Mean 
[95% CI] § 
Control 
Mean 
[95% CI] * 
Peak basal-septal strain 
-17.93 
[-18.75 to -17.11] 
-16.10 
[-17.30 to -14.89] 
§ p<0.05 
-20.10 
[-21.29 to -18.92] 
* p<0.05 
Peak mid-septal strain 
-19.01 
[-19.73 to -18.30] 
-17.35 
[-18.22 to -16.47] 
§ p<0.05 
-21.40 
[-22.27 to -20.53] 
* p<0.05 
Peak apical-septal 
strain 
-21.20 
[-22.32 to -20.07] 
-16.69 
[-18.13 to -15.24] 
§ p<0.05 
-21.42 
[-22.79 to -20.06] 
* p=0.73 
Peak apical-lateral 
strain 
-17.24 
[-18.72 to -15.77] 
-14.08 
[-15.58 to -12.59] 
§ p<0.05 
-17.33 
[-19.12 to -15.54] 
* p=0.16 
Peak mid-lateral strain 
-15.02 
[-16.22 to -13.81] 
-12.45 
[-13.83 to -11.07] 
§ p<0.05 
-17.75 
[-19.11 to -16.38] 
* p<0.05 
Peak basal-lateral strain 
-17.60 
[-19.11 to -16.10] 
-15.00 
[-16.40 to -13.60] 
§ p<0.05 
-21.41 
[-23.1 to -19.73] 
 * p<0.05 
Time of peak segmental 
strain [Inter-segmental 
time SD] 
45.60 
[41.43 to 49.77] 
51.85 
[44.53 to 59.16] 
§ p<0.05 
34.95 
[29.45 to 40.46] 
* p<0.05 
Time of peak segmental 
strain [Inter-segmental 
time difference] 
108.02 msecs 
[96.47 to 119.56] 
129.22 msecs 
[107.51 to 
150.94] 
§ p<0.05 
81.07 msecs 
[65.83 to 96.30] 
* p<0.05 
 
 
§
 Difference between pre- and post-dialysis patients 
* Difference between pre-dialysis patients and controls 
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Table 4.5: LV segmental circumferential strain 
 
 Pre-dialysis 
Mean 
[95% CI] 
Post-dialysis 
Mean 
[95% CI] § 
Control 
Mean 
[95% CI] * 
Peak antero-septal 
strain 
-25.75 
[-28.55 to -22.95] 
-27.93 
[-30.64 to -25.23] 
§
 p<0.05 
-24.75 
[-27.78 to -21.71] 
* p=0.63 
Peak anterior strain 
-22.00 
[-24.30 to -19.70] 
-20.75 
[-22.94 to -18.58] 
§
 p=0.20 
-20.50 
[-22.84 to -18.16] 
* p=0.24 
Peak lateral strain 
-17.54 
[-19.99 to -15.10] 
-12.24 
[-13.88 to -10.59]  
§
 p<0.05 
-17.35 
[-19.99 to -14.70] 
* p=0.37 
Peak posterior strain 
-12.92 
[-15.62 to -10.22] 
-12.63 
[-15.47 to -9.78] 
§ p<0.05 
-14.23 
[-16.77 to -11.69] 
* p=0.27 
Peak inferior strain 
-16.99 
[-19.04 to -14.95] 
-16.75 
[-18.67 to -14.82] 
§
 p=0.21 
-17.79 
[-20.66 to -14.92] 
* p=0.64 
Peak septal strain 
-23.45 
[-25.22 to -21.67] 
-23.15 
[-25.39 to -20.91] 
§
 p=0.31 
-22.65 
[--26.72 to -
18.59] 
* p=0.71 
Time of peak segmental 
strain [Inter-segmental 
time SD] 
63.02 
[50.64 to 75.39] 
55.95 
[47.90 to 64.00] 
§
 p<0.05 
35.34 
[28.10 to 42.58] 
* p<0.05 
Time of peak segmental 
strain [Inter-segmental 
time difference] 
164.27 msecs 
[125.49 to 
203.06] 
138.12 msecs 
[117.49 to 
158.75] 
§
 p<0.05 
84.41 msecs 
[64.82 to 103.99] 
* p<0.05 
 
 
§
 Difference between pre- and post-dialysis patients 
* Difference between pre-dialysis patients and controls 
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Table 4.6: LV segmental radial strain 
 
 Pre-dialysis 
Mean 
[95% CI] 
Post-dialysis 
Mean 
[95% CI] § 
Control 
Mean 
[95% CI] * 
Peak antero-septal strain 
36.16 
[30.36 to 41.96] 
47.81 
[35.99 to 59.62] 
§
 p=0.13 
43.44 
[36.27 to 50.62] 
*  p=0.11  
Peak anterior strain 
41.13 
[34.32 to 47.93] 
45.11 
[39.12 to 51.10] 
§
 p= 0..88 
54.57 
[47.21 to 61.93] 
* p<0.05 
Peak lateral strain 
46.50 
[37.82 to 55.18] 
46.93 
[40.58 to 53.28] 
§
 p=0.07 
62.20 
[55.29 to 69.11] 
* p<0.05 
Peak posterior strain 
45.25 
[36.64 to 53.86] 
47.17 
[40.24 to 54.10] 
§p<0.05 
63.15 
[55.83 to 70.47] 
* p<0.05 
Peak inferior strain 
40.78 
[34.39 to 47.12] 
44.56 
[37.74 to 51.37] 
§
 p= 0.2 
55.59 
[47.01 to 64.16] 
* p<0.05 
Peak septal strain 
36.04 
[30.46 to 41.63] 
41.57  
[35.33 to 47.82] 
§ p=0.08 
43.37 
[35.41 to 51.33] 
* p=0.12 
Time of peak segmental 
strain [Inter-segmental 
time SD] 
34.94 
[25.79 to 44.09] 
35.09 
[25.14 to 45.04] 
§
 p=0.05 
22.07 
[15.27 to 28.86] 
* p<0.05 
Time of peak segmental 
strain [Inter-segmental 
time difference] 
81.59 msecs 
[58.72 to 104.46] 
79.07 msecs 
[53.75 to 104.39] 
§
 p<0.05 
48.43 msecs 
[32.22 to 64.64] 
* p<0.05 
 
 
§ 
 Difference between pre- and post-dialysis patients 
* Difference between pre-dialysis patients and controls 
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Figure 4.13: Longitudinal time strain curves for patient 7. The top panel is pre-dialysis and the 
lower panel post dialysis.  
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Figure 4.14: Longitudinal time strain curves for patient 9. The top panel is pre-dialysis and the 
lower panel post dialysis.  
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Factors Associated with Strain Reduction 
Intradialytic peak longitudinal strain reduction was significantly associated with systolic 
BP, change in systolic BP during dialysis and the UF volume (see Table 4.7). During 
HD neither peak circumferential nor peak radial strain reductions were found to be 
significantly associated with intradialytic BP, UF volumes or dialysis vintage (see 
Tables 4.8 and 4.9). 
   
 
Table 4.7: Factors associated with peak longitudinal strain reduction during HD 
 
 Pearson’s 
Correlation 
R2 p-value Logistical 
Regression 
Coefficient 
p-value 
Absolute systolic BP -0.26 0.07 p<0.05 0.22 0.41 
Intradialytic systolic BP change 0.317 0.10 p<0.05 -0.18 0.54 
UF (mls/kg) 0.30 0.09 p<0.05 0.09 0.76 
Months on HD 0.05 0.002 p=0.71 0.13 0.80 
 
 
 
 
Table 4.8: Factors associated with peak circumferential strain reduction during HD 
 
 Pearson’s 
Correlation 
R2 p-value Logistical 
Regression 
Coefficient 
p-value 
Absolute systolic BP 0.20 0.04 p=0.18 0.04 0.9 
Intradialytic systolic BP change -0.03 0.001 p=0.87 -0.09 0.71 
UF (mls/kg) 0.14 0.02 p=0.34 0.04 0.9 
Months on HD -0.26 0.07 p=0.09 -0.88 0.13 
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Table 4.9: Factors associated with peak radial strain reduction during HD 
 
 Pearson’s 
Correlation 
R2 p-value Logistical 
Regression 
Coefficient 
p-value 
Absolute systolic BP 0.07 0.005 p=0.73 0.03 0.89 
Intradialytic systolic BP change -0.15 0.02 p=0.44 0.18 0.28 
UF (mls/kg) -0.22 0.05 p=0.91 0.05 0.81 
Months on HD -0.08 0.006 p=0.70 0.16 0.72 
 
 
 
Predictors of Intradialytic Systolic BP 
Within the cohort of 15 patients the UF volume ranged from 3mls/kg/hr to 86mls/kg/hr. 
The lowest documented intradialytic systolic BP ranged from 58mmHg to 140mmHg. 
On univariate linear regression analyses percentage strain reduction was not predictive 
of intradialytic BP (see Table 4.10).  
 
Table 4.10: Predictors of intradialytic systolic BP 
 Correlation 
Coefficient 
Significance 
% Reduction in peak longitudinal strain during HD 0.42 p=0.19 
% Reduction in peak circumferential strain during HD 0.19 p= 0.52 
% Reduction in peak radial strain during HD 0.03 p=0.91 
 
 
 
The intradialytic systolic BP reduction ranged from 6mmHg to 90mmHg. On univariate 
linear regression analyses both the percentage reduction in longitudinal strain and radial 
strain were significantly predictive of intradialytic systolic BP fall (see Table 4.11). 
Percentage reduction in longitudinal strain showed a positive correlation but radial 
strain showed a negative correlation, namely a greater fall in BP is seen in patients 
where peak radial strain shows little change during dialysis. 
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Table 4.11: Predictors of intradialytic systolic BP fall 
 Correlation 
Coefficient 
Significance 
% Reduction in peak longitudinal strain during HD 0.66 p<0.05 
% Reduction in peak circumferential strain during HD -0.32 p=0.19 
% Rise in peak radial strain during HD -0.70 P<0.05 
 
 
 
4.5 Discussion 
The prevalence of myocardial stunning in patients with CAD is high, cumulative and 
associated with an attendant risk of increased CV events and mortality. The same 
phenomenon has now been demonstrated in prevalent adult dialysis patients117 and ‘low 
risk’ non-diabetic, non-cardiac adult HD patients68 but until now there has been no 
evaluation of the risk in children. Compared with age matched controls I have 
demonstrated altered baseline myocardial function in uraemic children aged between 1 
to 17 years. During conventional 4 hour HD the myocardial function deteriorates further 
with biochemical evidence of ischaemic injury. The effect is global across all segments 
as opposed to a segmental distribution specific to an isolated coronary artery. The 
adverse impact on myocardial fibres within the LV wall is however specific with a 
predisposition to LV longitudinal shortening. The degree of myocardial dysfunction is 
associated with intradialytic blood pressure change and UF volumes. Nonetheless owing 
to an early compensatory hyperkinetic response in regions of the LV, preservation of 
circumferential shortening and increased radial thickening, the global LVEF did not fall, 
but arguably neither did it rise as one would expect following a significant 
hemodynamic challenge.  
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Left ventricular contraction relies on the co-ordinated shortening action of myocardial 
fibres in multiple directions: longitudinal shortening, radial thickening and 
circumferential shortening combined with torsion of the heart. The alignment of heart 
fibres and resultant patterns of regional strain is heterogeneous. The coronary blood 
supply to segments of the heart also shows significant variation. In this study regional 
wall motion assessment (RWMA) demonstrated significant dialysis induced regional 
myocardial dysfunction with preponderance for basal and apical segments. The strain 
analyses showed a reduction in peak strain but the difference was only significant in the 
longitudinal axis and all the segments were involved. With this discrepancy in 
segmental involvement there is an implication that 2D strain may be more sensitive 
measure than wall motion of mild segmental LV dysfunction. RWMA assessment is 
primarily an assessment in the longitudinal axis and uses the inward motion of 
endocardial borders as the sole marker of abnormal contraction.  However the visual 
estimation of wall motion can be very subjective and does not take into account wall 
thickening, twisting or transmyocardial heterogeneity. In contrast 2D speckle tracking 
provides a multi-axis assessment of LV function employing functional components that 
are not visible to the naked eye. The motion of myocardial tissue is measured indirectly 
by the motion pattern of speckles tracking along the direction of the wall, not along the 
ultrasound beam. This makes it both translation and angle independent with lower inter 
and intra-operator variability compared with RWMA131. Furthermore in a direct 
comparison of the two, assessments of wall motion cannot differentiate between active 
and passive movement of a myocardial segment whereas deformation has the ability to 
discriminate. In the heart this is particularly important as ventricular wall motion is 
position dependent. As the apical parts of the ventricle pull down the ventricular base, 
the wall motion increases from apex to base and thus some of the measured wall motion 
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effect in the base is the combined effect of contraction and also apical tethering. Thus 
even completely passive segments can show motion but not deformation. 2D speckle 
tracking is a novel method for assessing regional myocardial function with minimal 
experience in children. In adults however myocardial strain quantification has been 
validated against tagged cardiac magnetic resonance imaging135 and has been shown to 
be accurate and it is fast becoming the tool of choice in evaluating patients prior to 
cardiac resynchronisation, differentiating between hibernating myocardium and 
infracted myocardium. My limited experience in children was very positive and 
parallels these reports in adults. 
 
Longitudinally directed fibres are mainly located in the subepicardium and 
subendocardium regions of the LV. They only form a small proportion of the total 
ventricular myocardial mass but play a major role in the maintenance of normal ejection 
fraction. I found a selective reduction in longitudinal strain during HD. In simple terms 
this can be explained away by the heterogeneity of the heart architecture, however the 
apparent vulnerability of longitudinal shortening is not too dissimilar to other disease 
states and therefore unlikely to be either a coincidence or a normal variation. A degree 
of long-axis systolic dysfunction has been frequently reported in conjunction with 
diastolic dysfunction136. Regional reduction in the extent and velocity of long axis 
shortening has been shown to be a sensitive and specific finding after myocardial 
infarction137, 138. In hypertensive patients LV long axis function abnormalities have been 
found to present even before the onset of hypertension, but circumferential fractional 
shortening remain unchanged137. Both hypertension and diastolic dysfunction are 
features common to children on dialysis22, 27, 139 and their presence may in part be 
  
125
responsible for the findings or they share a common pathogenic pathway for 
longitudinal axis dysfunction dominance.   
 
One feature that distinguishes children from adults is the absence of significant 
epicardial atheromatous CAD. They do however share a high prevalence of risk factors 
for adult-type cardiovascular disease that have been associated with a reduced coronary 
flow reserve and thus a propensity to demand ischaemia140. Of these, hypertension, 
anaemia, hyperparathyroidism and hyperphosphataemia were significantly prevalent in 
these patients. Children can also display a constellation of altered functional and 
morphological cardiovascular features that predisposes them to ischaemic insults. LVH 
for example progresses to maladaptive cardiac remodeling characterized by decreased 
capillary density, subendothelial perfusion141 and decreased coronary contractile 
reserve142. Overt LVH was present in one patient and borderline hypertrophy in another 
3 patients. 5/17 of the patients were common to a study conducted by Shroff et al.119 
reporting findings of diminished arterial wall compliance and coronary and carotid 
artery calcification. Such vascular abnormalities are accepted markers of asymptomatic 
arteriosclerosis and mortality143 and perhaps indicative of coronary microcirculation 
abnormalities. Evidence for inappropriately raised sympathetic nerve activity in dialysis 
patients118 raises the possibility of an alternative explanation for the regional LV 
dysfunction, namely takotsubo or ’stress’ cardiomyopathy144. However Dasselaar et al 
demonstrated a fall in regional and global myocardial blood flow, 30 minutes into a HD 
session, in the absence of UF that preceded regional LV dysfunction68. This is the 
inverse of the causal sequence of takotsubo or ‘stress’ cardiomyopathy. In addition the 
children showed no evidence of apical ballooning, a feature typical of classical 
takotsubo cardiomyopathy. Nevertheless the effects of raised sympathetic nerve activity 
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may be relevant by mediating microvasculature derangement and vasospasm. I found no 
significant association between biochemical and cardiac risk factors and the severity of 
myocardial stunning. This is most likely due to the fact cardio-renal performance is 
influenced by a number of humoral and genetic factors145 that act collectively to exert 
an effect  but in isolation, particularly in paediatrics,  are too small to be detectable from 
our sample size.  
 
The major determinant of intradialytic BP is cardiac output and end diastolic volume 146 
but clearly regional LV function is important as evidenced by reports of reduced 
haemodynamic stability in patients developing myocardial stunning despite below 
average UF volumes129. Shoji et al found BP reduction during dialysis and not 
hypertension in adult HD patients as a factor that influenced survival negatively147. I 
found the UF volume and both the reduction and absolute intradialytic systolic BP to be 
related to dialysis induced longitudinal axis LV dysfunction, but only reduction in 
systolic BP was significantly associated with abnormalities in regional wall motion. 
These differences are most likely related to technique differences. 2D speckle tracking 
is slowly gaining credence over RWMA with improved accuracy and reproducibility 
qualities. It also has the ability to detect subtle and milder abnormalities in regional LV 
dysfunction, particularly those secondary to ischaemia, and thus even weak correlations 
became more apparent. Peak segmental strain was not predictive of absolute systolic BP 
but percentage changes in LV longitudinal shortening and radial thickening were both 
found to be predictive of intradialytic blood pressure changes.  The implication is that 
actual BP is not as important as the failure to maintain BP in initiating and propagating 
myocardial stunning during dialysis. Children appear to be different to adults, with a 
more direct relationship between BP and UF volumes. In addition, as a consequence of 
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residual renal function, some exist closer to their dry weight and are thus very sensitive 
to fluid shifts during dialysis. Combined with a poorly compliant left ventricle27 and 
peripheral conduit vessels32, 33, abnormal vascular tone, UF mediates a reduction in 
cardiac output and BP. In the face of an attenuated coronary reserve, ischemia prevails 
when the hemodynamic demand of HD is not met by an adequate increase in 
myocardial blood flow.  
 
There is considerable evidence alluding to the value of both CRP 39 and baseline cardiac 
troponin as markers of cardiovascular disease and mortality in ESRD. An acute rise in 
cardiac troponin levels in HD patients is also indicative of sub-clinical myocardial 
ischaemic injury 58, 59, 63. I found elevated levels of high sensitivity CRP in half of the 
dialysis patients that were tested and a rise in cardiac Troponin I (cTnI) levels in 25%. 
Elevated plasma cardiac troponins levels are usually only seen 6-12 hours after the 
acute injury. However in this study post-dialysis plasma samples were taken 15minutes 
after the end of the HD session and this may explain my failure to demonstrate a rise in 
cardiac troponin I levels in more of the patients. In the patients that did demonstrate a 
rise in plasma cardiac enzmyes levels it is conceivable that the cardiac insult occurred 
early in the 4hour HD session and thus levels were detectable post-dialysis. An earlier, 
alternative marker of cardiac injury is mechanical synchronisation of LV contraction. 
Dssynchronous left ventricular long axis function is common in patients with chronic 
stable coronary artery disease136. In fact the presence and localisation of asynchrony 
correlates closely with reversible abnormalities on thallium myocardial perfusion 
scanning138 and precedes ECG changes or symptoms and changes in myocardial systolic 
amplitude of motion. Asynchrony is believed to a sensitive and earlier marker of 
ischaemia148. I observed an exaggerated dssynchrony index in longitudinal, 
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circumferential shortening and radial thickening at the end of HD. This may reflect 
ischaemic injury that was detected earlier than more traditional biochemical markers of 
cardiac injury. Within this context it has the potential for becoming very useful in the 
clinical environment in identifying ‘at risk’ patients. 
 
 
4.6 Study Limitations 
This was a preliminary study looking at regional LV dysfunction in children on HD and 
the sample size was small. Nevertheless the study was adequately powered for the 
primary outcome. RWMA and analysis was repeated twice in the same patient and the 
results showed concordance in the localization of abnormalities but the number of 
segments involved differed. This may indicate poor reproducibility or conversely is the 
consequence of differences in intra-patient UF volumes and intradialytic hemodynamic 
parameters between treatments. 2D speckle tracking analyses of the same patients were 
again consistent with findings from RWMA but the prevalence of segmental myocardial 
dysfunction was higher. This is likely to be due to the fact that 2D speckle tracking 
screened LV function in 3 axes and the assessment incorporated an additional 
parameter, dyssynchrony index, and was thus a more sensitive test. 
 
I have already alluded to the limitations of RWMA. However looking specifically 
within the context of children, 2D speckle analyses are also at risk of inaccuracy. 
Normally, the resting heart rate is influenced by the age of the child and the younger the 
child the higher their resting heart rate. During dialysis patients become tachycardic. 
The optimal frame rate for speckle tracking seems to be 50–70 frames per second, 
however in the face of tachycardia this could result in under sampling. In an attempt to 
manage this problem I tried to use higher frame rates but this resulted in a reduction of 
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spatial resolution and in some patients this had to be abandoned as a result of less than 
optimal speckle tracking. In essence neither assessment is perfect but the gold standard 
for assessing functional change, magnetic resonance imaging, is technically impossible 
in patients while they are receiving HD. Of the two assessments speckle tracking shows 
more promise in detecting regional LV function, however prior to recommending it for 
general application 2D speckle tracking use must be validated in children. 
 
In this study I have made two assumptions. Firstly, having extrapolated from adult data, 
I have implied that HD in children is also associated with reduced myocardial blood 
flow. I have also assumed based both on negative findings or the absence of reports in 
the literature that none of the children in the cohort had significant epicardial CAD. 
Both of these questions could have been answered by subjecting the children to 
angiography or perfusion imaging but I elected not to do this due to the practical 
implications and severe reluctance from both the patients and dialysis nurses. Of the 
two, perfusion imaging may be considered to be less invasive, however adult data 
suggests that myocardial scintigraphy is imperfect in detecting CAD in patients with 
ESRD [De Lima JJ,03] and indeed doubts about applicability in patients with more 
severe CKD has led to renal disease currently not being categorised in the most recent 
‘Appropriateness Criteria for Stress Echocardiography’ recommendations149.  
 
 
4.7   Conclusion 
I have shown for the first time that paediatric patients receiving conventional HD suffer 
from dialysis induced myocardial stunning. As in adults, this reflects the degree of HD 
induced haemodynamic instability. This data, in combination with previous adult 
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studies suggest that even in the absence of conventional epicardial coronary artery 
disease the characteristic cardiovascular phenotype in uraemic HD patients is severe 
enough to limit the microvasculature response to haemodynamic stress and predisposes 
to significant demand myocardial ischemia. 
 
Myocardial stunning is progressive with raised attendant mortality. In any serious 
attempt to modify the cardiovascular burden in dialysis patients we will require an 
accurate method for detecting ischaemic myocardial injury. In my limited experience 
the novel method of 2D speckle tracking was superior to the traditional method of 
regional wall motion assessment as it is able to offer a more comprehensive assessment 
of LV function combined with the possibility of detecting ischaemic myocardial injury 
in its early stages.  
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Chapter Five 
Moderators of Intradialytic Morbidity 
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5.1 Hypotheses 
 Manipulating the HD prescription can improve intradialytic morbidity during 
paediatric dialysis 
  The use of sodium and UF profiles improves cardiovascular stability 
 The prescribing of intradialytic mannitol reduces the frequency and severity of 
intradialytic symptoms 
  The application of sequential dialysis during the course of the dialysis treatment 
improves the UF potential  
 
 
5.2 Introduction 
The development of intradialytic symptoms and hypotension can result in premature 
discontinuation of treatment and delivery of sub-optimal dialysis with an attendant 
adverse impact on health150. Broadly speaking dialysis failure (in the absence of clotting 
the extracorporeal circuit) has two aetiologies, dialysis dysequilibrium and UF mediated 
cardiovascular decompensation. The challenge is that during an acute episode 
symptoms can be non-discriminatory and their pathophysiological mechanisms obscure. 
Thus developing strategies to prevent or manage dialysis failure is both difficult and 
may have variable results. The recognised measures for improving haemodynamic 
stability during HD, such as avoiding food during dialysis151 and treating intradialytic 
hypocalcaemia16 are of limited value. Experience with newer methods such as sodium 
and UF profiles78 and intradialytic mannitol are inconsistent and limited in paediatrics. 
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5.3 Subjects and Methods 
5.3.1 Prevalent chronic HD patients 
I developed a standardized practice for prescribing chronic HD at the Hospital for Sick 
Children, Toronto. After 8 months the data from these dialysis treatments was collected 
and analysed. I included all children on HD for a minimum of one month, excluding 
those patients receiving nocturnal HD and those that were acutely unwell and/or in the 
paediatric intensive care unit. Ethics approval for this study was granted by the local 
research ethics board and informed consent was obtained from patients or their 
guardians. 
 
Patients 
Baseline characteristics of the patients and dialytic treatments are listed in Table 5.1. A 
total of 11 patients were studied, 5 female and 6 male. The underlying renal disease was 
focal segmental glomerulosclerosis (1 patient), autosomal recessive polycystic kidney 
disease (1 patient), renal dysplasia (4 patients), chronic drug toxicity and BK virus 
nephropathy secondary to cardiac transplant (1 patient), membranous 
glomerulonephritis (1 patient), ANCA negative glomerulonephritis (1 patient), 
unknown (2 patients). 5/11 patients were polyuric (daily urine output >1.5mls/kg/hr); 
one had panhypopituitarism; one had a chronic history of intradialytic cramping; one 
had been treated with a second heart transplant and had evidence of significant right 
ventricular dilatation on a peak dobutamine stress test but normal right and left 
ventricular function at rest. The resting heart rate was no different between the cardiac 
transplant patients and the remaining patients. Throughout the observation period 6 
patients were normotensive without medication, 2 patients were on one antihypertensive 
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and 3 patients were on two antihypertensives. 3/11 patients had evidence of ventricular 
or septal hypertrophy. 
 
Table 5.1: Baseline characteristics of patients and their dialytic treatments 
 
Sex (M/F) 5/5 
Age (years) 12.8 ± 2.93 
Dry weight (kg) 40.2 ± 15.6 
Urine output (yes/no) 5/5 
Urine output (mls/kg/hr) 1.61 ± 0.81 
Pre-dialysis plasma haemoglobin (g/l) 94.8 ± 11.9 
Pre-dialysis plasma albumin (g/l) 35.8 ± 4.63 
Pre-dialysis plasma ionised calcium (mmol/l) 1.24 ± 0.16 
Mean gross UF (mls/session) 1475 ± 937 
Mean gross UF (%body weight /session) 4.77 ± 2.09 
Blood flow rate (mls/min) 120-350 
Dialysate flow rate (mls/min) 200-650 
Kt/V 1.71 ± 0.27 
Mean Systolic BP at the start of dialysis (mmHg) 113 ± 20.5 
Mean Diastolic BP at the start of dialysis (mmHg) 68.1 ± 12.3 
Mean Heart rate at the start of dialysis (beats/min) 100 ± 19.2 
 
 
 
The Standardised HD Prescription 
All patients were dialysed using the Fresenius 2008K® or 2008H®. Patients received 
HD for 3hrs, 4 times per week or for 4hrs, 3 times per week. All dialysis membranes 
were high flux, triacetate cellulose or polysulfone membranes. Dialysis flow rates 
varied between 200 to 650mls/min but were kept constant by a dialysate to blood flow 
ratio of 2 to 2.5. Blood flow rates were calculated to provide an estimated urea 
clearance of 4mls/kg/min. The dialysis prescription was adjusted monthly to achieve a  
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urea reduction ratio between 65 to 80% and Kt/V urea between 1.2 and 1.6 (calculated 
from Daugiradas single pool kinetics)115. All patients received heparin as standard 
anticoagulation or no heparin if they were at a risk of bleeding. Patients were dialysed 
against 35mmol/l bicarbonate, 1.25mmol/l calcium, with a small quantity of acetate in 
the acidic component to stabilise the dialysate. The dialysate temperatures were set at 
constant value of 37.5˚C. Patients were permitted to consume one meal during the first 
hour of their treatment. Mannitol was given if the pre-dialysis plasma urea 
concentration was greater than 35mmol/l or if the patient experienced symptoms 
suggestive of dialysis dysequilibrium (severe headaches or altered levels of 
consciousness) on at least two separate occasions during previous dialysis treatments. 
For these patients 1g/kg mannitol was administered intravenously during the first hour 
of the first weekly dialysis session or 0.5g/kg during two dialysis sessions per week. 
 
UF Profiles 
The prescribed UF rate was determined from the interdialytic weight gain plus the 
volume of fluid given during the dialysis treatment including priming fluid, blood 
products and nutrition. Pre-programmed Fresenius 2008K UF profile patterns outlined 
in Figure 5.1 were used (when the Fresenius 2008H machine was used the UF profiles 
were adjusted to match those on the 2008K model). As shown profile 3 was a 
decreasing step pattern, profile 6 an alternating high/low UF rate and profile 2 a 
decreasing linear pattern. The maximum UF rate in any programme did not exceed 1.5 
times the average rate. 
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Figure 5.1: UF profiles 
 
 
Dialysate Sodium Ramping 
All standard treatments were prescribed a universal dialysate sodium gradient of 
148mmol/l at the start of dialysis, ending with a concentration of 138mmol/l. During the 
linear sodium profile the dialysate sodium was decreased at a linear but constant rate to 
the final concentration. During the step profile the starting dialysate sodium was 
continued until the last 30 minutes of dialysis and then dropped in one step to the final 
concentration.   
 
Study Protocol 
A step wise approach to sodium and UF profiling was introduced for all the patients.  
Step 1: linear sodium profile + UF profile 3 for one week, followed by one week of step 
sodium profile + UF profile 3. The patient was then continued on the regimen with the 
least intradialytic symptoms, unless 2 treatment failures occurred, as defined below. In 
the event of two treatment failures the patient moved to Step 2, namely: linear sodium 
profile + UF profile 6 for one week, followed by one week of step sodium profile + UF 
profile 6. The patient again continued on the regimen with the least intradialytic 
symptoms, unless a further 2 treatment failures occurred. The patient then moved to 
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Step 3: linear sodium profile + UF profile 2 for one week, followed by one week of step 
sodium profile + UF profile 2. This was continued on the regimen with the least 
intradialytic symptoms, unless 2 treatment failures occurred. Finally Step 4: linear 
sodium profile + UF profile 0 (constant UF rate) for 1 week, followed by one week of 
step sodium profile + UF 0. This was continued on the regimen with the least intra-
dialytic symptoms, unless 2 treatment failures occurred. At this point the patient exited 
form the study protocol.  
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2 Treatment Failures 
STEP 1 
w Linear sodium profile + UF profile 3 for one week 
w Step sodium profile + UF profile 3 for one week 
STEP 2 
w Linear sodium profile + UF profile 6 for one week 
w Step sodium profile + UF profile 6 for one week 
STEP 3 
w Linear sodium profile + UF profile 2 for one week 
w Step sodium profile + UF profile 2 for one week 
STEP 4 
w Linear sodium profile + UF profile 0 for one week 
w Step sodium profile + UF profile 0 for one week 
2 Treatment Failures 
2 Treatment Failures 
Study Protocol 
  
139
 Treatment failure was defined as, i) premature discontinuation of the dialysis session, 
ii) intradialytic hypotension requiring a fluid bolus and iii) failure to achieve the dry 
weight only if the UF goal was less than or equal to 5% of the dry weight. 
 
During each dialysis treatment the patient’s heart rate, gross UF volume and BP was 
recorded hourly, at the time of an adverse event prior to any nursing intervention, and 
after recovering from it. A single BP reading was taken with an automated Dinamapp 
machine and a cuff adjusted for size. The first Task Force 5th percentile systolic blood 
pressure measurements, adjusted for age and sex8 were used to define intradialytic 
hypotension except in a single patient with co-existing panhypopituitarism in whom the 
cut-off systolic blood pressure was set at 75mmHg. In the event of a hypotensive 
episode UF was stopped and if the BP failed to recover after 15 minutes or the patient 
began to clinically deteriorate, a bolus of normal saline was administered.  
 
In addition the following information was recorded during each treatment: i) description 
of intradialytic symptoms, ii) nature of any dialysis nurse intervention, iii) changes to 
the UF rate, and iv) administration of mannitol, blood products, or fluid boluses. At the 
end of the dialysis treatment the patient’s weight and final UF volume was recorded. 
The dry weight was assessed monthly by a clinical assessment combined with a review 
of post-dialysis weights at which the patient displayed no symptoms indicative of 
under-hydration at the end of their treatment.  
  
Outcome Measures 
The outcome measures were categorized into 4 distinct groups: 
OUTCOME 1 - occurrence of intradialytic symptoms and/or temporary suspension UF  
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OUTCOME 2 - administration of saline bolus and/or episode of hypotension 
OUTCOME 3 - success in achieving the desired dry weight 
OUTCOME 4 - UF volume expressed as a percentage of the dry weight calculated from 
the gross UF volume as the denominator  
 
The primary endpoints were a comparison of sodium ramping and UF profiles 2,3 and 6 
against the defined outcome measures and to determine the effects of intradialytic 
mannitol on these outcomes. The secondary endpoint was determining the volume of 
UF that was achievable by our standardized dialysis prescription. Polyuric patients were 
excluded from the analyses for OUTCOMES 3 and 4. 
 
Statistical Analyses 
All values of continuous variables were presented as mean ± standard error or 95% 
confidence interval. A paired t test was used to determine whether there were significant 
differences between continuous variables at the 95th confidence interval. The incidence 
of observed events was expressed as a percentage, dividing the number of sessions 
during which an event occurred over the total number of sessions. For a more robust 
statistical comparison of the impact of the different treatments on outcome, a repeated 
measures Generalized Estimating Equations model was fitted to the data to account for 
the internal correlation structure of the data as a result of having repeated measures per 
subject. Treatment comparisons of linear versus step, 4 different sodium profiles, UF 
profile 0 versus 2, 3 and 6 and mannitol versus no mannitol were analysed and 
expressed as an odds ratio. A repeated measures ANOVA model was fitted to the 
percent dry weight data, our only continuous outcome. All statistical tests were two 
tailed with a p-value less than or equal to 0.05 taken to indicate significance. 
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5.3.2 Children prone to dialysis failure 
Patients 
During the previous study any child that had premature discontinuation of their dialysis 
treatment at minimum once weekly, on 3 separate occasions per treatment month, was 
selected. Of the 11 children, 6 were identified as being prone to severe intradialytic 
symptoms or hypotension and recruited for this study. The patient demographics are 
shown in Table 5.2. Ethics approval for this study was granted by the local research 
ethics board and informed consent was obtained from patients or their guardians. 
 
Dialysis Prescriptions 
All patients were dialysed against the standardised HD prescription for 3 hours 4 
times/week or 4 hours 3 times/week using high flux membranes with dialysis flow rates 
between 200 to 650mls/min and blood flow rates adjusted to provide an estimated urea 
clearance of 4mls/kg/min. All patients were dialysed against 35mmol/l bicarbonate with 
a small quantity of acetate in the acidic component to stabilise the dialysate, 1.25mmol/l 
calcium solution and decreasing sodium profiles of 145-148mmol/l at the onset falling 
to 135-138mmol/l in a step-wise manner. The dialysate temperature was set at 37.5˚C 
and treatments were programmed using a constant UF (UF profile 0).  
 
All 6 patients underwent a trial of prophylactic mannitol and sequential dialysis.  
Mannitol was given if the pre-dialysis plasma urea concentration was greater than 
35mmol/l or if the patient experienced symptoms suggestive of dialysis dysequilibrium 
(severe headaches or altered levels of consciousness) on at least two separate occasions 
during previous dialysis treatments. For these patients 1g/kg mannitol was administered 
intravenously during the first hour of the first weekly dialysis session or 0.5g/kg during 
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two dialysis sessions per week. Mannitol was diluted in saline using 50mls of normal 
saline per 10g of mannitol. In children with repeated episodes of UF failure sequential 
dialysis was prescribed at the start or end, for 30 minutes during 3hr treatments or 60 
minutes during 4hr treatments. 
 
Table 5.2: Children prone to dialysis failure: patient demographics 
 
VSD: ventricular septal defect 
 ASD: atrioseptal defect 
 LVH: left ventricular hypertrophy 
 
Patient Age Primary Renal 
Disease 
Co-morbidities Urine 
Output 
(mls/kg/d) 
Cardiac 
Echocardiogram 
[Antihypertensives] 
1 11 Membranous 
glomerulonephritis 
Developmental delay 
Syndromic 
Bone marrow suppression 
Panhypopituitarism 
0 Normal 
 
[None] 
2 16 ANCA positive 
glomerulonephritis  
Absence seizures 
Poor adherence 
0 Mild septal LVH 
 
[Amlodipine & 
Atenolol] 
3 7 ? Nephronophthisis G6PD deficiency 
Hepatic fibrosis 
Subdural effusions with 
cerebroperitoneal shunt 
in-situ 
Intradialytic hypertension 
2.9 Normal 
 
[Atenolol & 
Enalapril] 
4 15 Hypo-
complementemic  
glomerulonephritis  
Biliary hypoplasia  
Failed liver transplant 
Splenomegaly & portal 
hypertension. Recurrent 
haematemesis secondary 
to oesophageal varices 
Pancytopenia 
Scurvy and  malnourished 
0.2 Mild concentric 
LVH 
 
[None] 
5 14 Autosomal 
recessive 
polycystic kidney 
disease 
Caroli’s disease with 
hepatic fibrosis & retinal 
dystrophy 
Splenomegaly & portal 
hypertension 
Pancytopenia 
0 Normal 
 
[None] 
6 11 Solitary ectopic 
dysplastic kidney 
Female hypospadius 
Poor adherence 
ASD, VSD 
Scoliosis 
1.8 Small restrictive 
VSD. No LVH 
 
[None] 
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Study Protocol 
During dialysis the patient’s heart rate and BP was recorded hourly throughout 
treatment, at the time of symptoms and upon recovery. The first Task Force 5th 
percentile systolic BP measurements8 defined intradialytic hypotension except in Patient 
1 whose cut-off systolic BP was set at 75mmHg. In the event of a hypotensive episode 
UF was stopped and if the BP failed to recover after 15 minutes or the patient began to 
clinically deteriorate, a bolus of normal saline was administered. At the end of the 
dialysis treatment the patient’s weight and final gross UF volume was recorded. The dry 
weight was assessed monthly and qualified from a clinical assessment combined with a 
review of the post-dialysis weight and the onset of symptoms indicative of under-
hydration following dialysis.  
 
Outcome Measures 
The outcome measures were categorized into 3 groups:  
OUTCOME 1 - intradialytic symptoms (abdominal pain, cramps, headaches, loss of 
consciousness or change in behaviour) 
OUTCOME 2 - hypotension or premature discontinuation of dialysis, due to persistence 
of hypotension/ symptoms in spite of a single fluid bolus 
OUTCOME 3 - percentage dry weight removed (calculated as gross UF volume divided 
by the estimated dry weight). 
 
Statistical Analyses 
All values of continuous variables were presented as mean ± standard error.  A paired t 
test was used to determine whether there were significant differences between 
continuous variables at the 95th confidence interval. For a statistical comparison of the 
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impact of the different treatments on outcome, a repeated measures Generalized 
Estimating Equations model was fitted to the data to account for the internal correlation 
structure of the data as a result of having repeated measures per subject. A repeated 
measures ANOVA model was fitted to the percent dry weight data, our only continuous 
outcome. All statistical tests were two tailed with a p-value less than or equal to 0.05 
taken to indicate significance. 
 
 
5.4 Results 
5.4.1 Prevalent chronic HD patients 
A total of 506 dialysis treatments were reviewed with 162/506 (32%) from polyuric 
patients. A linear sodium profile of 148mmol/l to 138mmol/l was used in 219/506 
(43%) treatments and a step profile in 287/506 (57%). UF profile 2 was used in 103/506 
(20%) treatments, UF profile 3 in 137/506 (27%) treatments, UF profile 6 in 19/506 
(4%) treatments and no UF profile in 287/506 (57%) treatments. Mannitol was 
prescribed in 48/502 (9%) treatments.  
 
The prevalence of intradialytic symptoms (OUTCOME 1) was 26%. Intradialytic 
hypotension or administration of a fluid bolus (OUTCOME 2) occurred in 19%. The 
desired dry weight was achieved in 124/344 (36%) treatments from non-polyuric 
patients. Using our standardized dialysis prescription combining sodium and UF 
profiling and intra-dialytic mannitol we achieved UF goals ranging from 3.2% to 9.7% 
of the dry weight (OUTCOME 4). Analysed individually the mean UF volume for all 
the interventions were greater than the current recommendations of 5% from the 
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European Haemodialysis Guidelines152 with mannitol achieving the highest mean UF 
volume (see Table 5.3). 
 
The overall treatment failure rate was 33% (167/506 treatments). Treatment failure due 
to premature discontinuation of the dialysis session occurred in 20/506 treatments and 
of these 5 were due to hypotension episodes and 15 due to intradialytic symptoms. 
Failure due to the development of intradialytic hypotension requiring a saline bolus 
occurred in 37/506 treatments. Finally 115/506 treatments failed to achieve the desired 
dry weight, despite a target UF goal less than 5%. The treatment protocol resulted in 
significant morbidity in one patient who had a history of panhypopituitarism, bone 
marrow failure and was prone to hypotensive episodes. He became unconscious during 
4 dialysis treatments. This was associated with marked hypotension and bradycardia 
and was thought to be secondary to a Bezold-Jarisch reflex. Owing to the severity of his 
symptoms he was excluded from the protocol prematurely but his data was included and 
analysed up to and including the 4th episode. One patient developed intradialytic 
symptoms and interdialytic fatigue with UF profile 6 on two consecutive dialysis 
sessions and refused further treatments with UF profile 6.   
 
Linear Versus Step Sodium Ramping 
There was no significant difference between linear and step sodium ramping and the 
onset of intradialytic symptoms. Compared with the step profile the linear profile 
increased the odds of hypotensive episodes or premature discontinuation of treatment by 
27% (see Table 5.4). The likelihood of achieving the dry weight was no different 
between the step and linear sodium profiles and the mean UF volume for both was 
virtually identical at 5.4% of estimated dry weight (see Table 5.3).    
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UF Profiles 
The UF profiles were no better than a constant UF rate (UF profile 0) in preventing 
intradialytic symptoms, hypotensive episodes or premature discontinuation of dialysis 
(see Table 5.4). UF profile 2 was the least effective in achieving the desired dry weight, 
reducing the odds by 40% when compared to a constant UF rate, reducing the odds by 
60% compared with profile 3 and reducing the odds by 36% when compared against UF 
profile 6. The latter was not statistically different and neither were the remaining UF 
profile comparisons. Profile 3 increased the odds of achieving the dry weight by 50% 
compared with a constant rate and UF profile 6 was virtually identical to a constant UF 
rate (see Table 5.4). The mean UF was however higher with all 3 profiles compared to 
UF profile 0, but only the difference between profile 2 and 0 were statistically 
significant (Table 5.3). Therefore all 3 UF profiles had mean UF volumes greater than 
5% of the dry weight but none of them significantly increased the odds of achieving the 
dry weight.  
 
Mannitol 
Compared to dialysis treatments without mannitol, the administration of mannitol 
reduced the odds of intradialytic symptoms by 64% (p<0.05) but did not improve the 
odds of preventing intradialytic hypotension or achievement of the desired dry weight 
(see Table 5.4). The mean UF volume was statistically greater with mannitol compared 
to those without, with a mean of 6.2% of the dry weight (see Table 5.3). 
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Table 5.3:  Comparison of the Percentage Dry Weight Removed  
 
 
 
 
 
 
 
 
 
 
 
 
 
A : the difference between UF profile 0 and profile 2 was significant (p<0.05) 
* : the difference between mannitol versus no mannitol was significant (p<0.05) 
[For the remainder the differences were not statistically significant] 
 
 
Table 5.4: Odds ratios of defined outcomes against each dialytic intervention 
 
 
 
 
 
 
  
 
 
 
 
 
 
Outcome 1:  Odds of intradialytic symptoms 
Outcome 2:  Odds of hypotensive episode and /or administration of saline bolus  
Outcome 3:  Odds of successfully achieving the desired dry weight 
 All patients excluding those with polyuria 
 Mean [95% CI] 
Linear sodium 5.41  [4.97 – 5.86] 
Step sodium 5.37  [4.96 – 5.78] 
UF profile 0 5.03  [4.68 - 5.38] A 
UF profile 2 5.99  [5.49 – 6.49] 
UF profile 3 5.61  [4.98 – 6.25] 
UF profile 6 6.11  [5.26 – 6.96] 
Mannitol 6.18  [5.39 – 6.9] * 
OVERALL 5.39  [5.07 – 5.71] 
 OUTCOME 1 OUTCOME 2 OUTCOME 3 
Linear v Step sodium 1.61  (p=0.10) 1.27  (p=0.05) 1.25  (p=0.54) 
UF profile 2 v 0 1.58  (p=0.16) 0.77  (p=0.28) 0.60  (p<0.05) 
UF profile 3 v 0 1.66  (p=0.28) 0.91  (p=0.81) 1.46  (p=0.24) 
UF profile 6 v 0 1.47  (p=0.6) 1.50  (p=0.21) 0.95  (p=0.82) 
UF profile 2 v 3 0.95  (p=0.87) 0.85  (p=0.78) 0.41  (p<0.05) 
UF profile 2 v 6 1.08  (p=0.9) 0.51  (p=0.23) 0.64  (p=0.07) 
UF profile 3 v 6 1.13  (p=0.74) 0.61  (p=0.11) 1.54  (p=0.14) 
Mannitol v no mannitol 0.36  (p<0.05) 1.06  (p=0.89) 1.15  (p=0.82) 
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5.4.2  Children prone to dialysis failure 
Of 399 dialysis treatments intradialytic mannitol was given in 57 (17%) and sequential 
dialysis in 44 (11%). Intradialytic mannitol significantly increased mean treatment UF 
volume (see Table 5.5), 86% of the treatments achieved UF volumes greater than 
average for that individual patient and one third achieved their dry weight. Mannitol 
halved the odds of intradialytic symptoms and hypotension/premature discontinuation 
of dialysis (see Table 5.6). Sequential dialysis also halved the odds of intradialytic 
symptoms (see Table 5.6). Intradialytic hypotension developed in 50% of the treatments 
but dialysis was only prematurely discontinued in 2% of treatments and 2 out of 3 
treatments achieved UF volumes greater than the average for an individual patient (see 
Table 5.5).  
 
 
Table 5.5: Prevalence rates of intradialytic morbidity and achieving the desired UF goal with 
intradialytic mannitol and sequential dialysis  
 
Intervention Symptoms 
 
Hypotension 
 
Premature 
discontinuation 
of treatment 
Dry Weight 
Achieved 
UF as Percentage 
Dry Weight 
Mean [95% CI] 
Mannitol 6/57(11%) 3/57 (5%) 3/57 (5%) * 9/29(31%) 5.55 [5.04 – 6.06] 
Sequential 1/44 (2%) 23/44 (53%) 1/44 (2%) 18/44 (41%) 10/21(48%) 
4.23 
[3.66 – 4.80] 
 
 
† Average UF volume for each patient was calculated from the total number of dialysis  
session over a 6 month period.  
 
* excluding polyuric patients  
 
 
 
 
 
  
149
Table 5.6: Impact of mannitol and sequential dialysis on intradialytic symptoms and 
hypotension  
 
 
 
 
 
Outcome 1:  Odds of intradialytic symptoms 
Outcome 2:  Odds of premature dialysis discontinuation and/or administration of saline bolus  
and/or episode of hypotension 
 
 
Table 5.7: Chi-squared analysis of interventions mannitol and sequential dialysis and outcomes 
 
 
 
 
 
 
Degrees of freedom: 1 
p value is the probability of the null hypothesis being true 
 
Outcome 1:  Odds of intradialytic symptoms 
Outcome 2:  Odds of premature dialysis discontinuation and/or administration of saline bolus  
and/or episode of hypotension 
 
 
In patient 1 the odds of intradialytic hypotension was 23 times greater than the group 
risk. His pre-dialysis systolic BP ranged between 85-105mmHg and his interdialytic 
weight gain frequently exceeded 5% his dry weight. The patient’s predisposition for 
hypotension was often during the second hour of dialysis and was often associated with 
bradycardia. Sequential dialysis reduced intradialytic symptoms but not hypotension. 
Twice weekly mannitol reduced the odds of symptoms and hypotensive episodes but the 
 OUTCOME 1 OUTCOME 2 
Mannitol v no mannitol 0.44  (p<0.05) 0.56  (p<0.05) 
Sequential v no sequential 0.47  (p<0.05) 2.45  (p<0.05) 
 OUTCOME 1 OUTCOME 2 
Mannitol  2.64   (p=0.10) 
0.35  
(p=0.18) 
Sequential  1.16  (p=0.20) 
1.61  
(p=0.28) 
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UF potential was unchanged. As an isolated case I then elected to trial intradialytic 
midodrine. In the event of a declining BP 2.5mg of oral midodrine was given. If the BP 
failed to improve within 30 minutes or fell below 75mmHg a further 2.5mg dose was 
given. A cut-off of 7.5mg total dose was applied per 3 hour treatment and no midodrine 
was given in the final 30 minutes irrespective of BP. On using intradialytic midodrine 
no intradialytic symptoms were observed and the mean treatment UF volume increased 
from 3.74% to 3.96%, achieving higher than average UF volumes in 95% of the 
treatments and the desired dry weight in one third of the treatments (see Table 5.6). 
During 18 of 20 observed dialysis sessions a 2.5mg oral dose of midodrine produced a 
10-15mmHg increase in the systolic BP within 30 minutes of administration and no 
adverse effects were reported in the intradialytic or interdialytic period.   
 
 
5.5 Discussion 
The uraemic milieu impairs compensatory responses to haemodynamic stress with 
ineffective venoconstriction, inadequate cardiac refilling, reduced plasma refilling and 
activation of the sympaticoinhibitory Bezold–Jarisch reflex leading to sudden 
hypotension153. In paediatrics more often than not we are faced with the additional 
challenge of large UF goals. During standard 4 hour HD sessions this combination can 
result in decompensation and morbidity. I have shown both in prevalent dialysis patients 
and in high risk children that are prone to hypotension that manipulation of 
conventional HD prescriptions can improve the dialysis experience. 
 
Children may not understand or appreciate the long-term implications of chronic 
hypervolaemia and are often non-adherent to their fluid restrictions. The excess fluid 
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accumulates both in the intravascular and extravascular compartments, but only the 
former is amenable to UF during dialysis. During their treatments they often do not 
voice the onset of symptoms until they are severe or associated with hypotension. 
Children have compliant high capacitance vessels and hypovolaemia may occur 
suddenly with little warning. This reduces the opportunity to change the UF rates before 
the intravascular volume becomes compromised. As a result, cautious UF goals of 5% 
of the dry weight have been recommended152. In paediatrics, Jain et al were the first to 
challenge this recommendation by introducing the concept of adjusting UF rates 
according to changes in RBV43. They reported reduced dialysis associated morbidity 
providing the UF volumes did not result in a blood volume change greater than 8% in 
the first hour and 12% over the dialysis session. In comparison I have demonstrated that 
through the use of dialysis regimens combining sodium ramping, UF profiles and 
intravenous mannitol, UF volumes of up to 9% of the dry weight can be achieved.  
The intravascular compartment is continuously changing during dialysis as fluid is 
removed by UF but refilled from the interstitial compartment. The total circulating 
blood volume during a dialysis treatment is therefore greater than that of a 
normovolaemic individual with a significant inter-patient and intra-patient variation in 
the pattern of RBV change151. Therefore any dialytic measure that promotes vascular 
refilling or improve cardiovascular stability should in theory help to restore 
normovolaemia and increase the UF potential in dialysis patients. Sodium profiling 
provides a diffusive sodium influx at the start of dialysis to counterbalance the rapid 
decline in plasma osmolarity from clearance of uraemic solutes, ending with a low 
dialysate sodium concentration to encourage diffusive clearance of the sodium load. 
Compared with a constant dialysate sodium concentration, ramps have been associated 
with increased stability of the intradialytic blood volume and reduced intradialytic 
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cramps and interdialytic fatigue in adults78, 127 and in older children78. This is in keeping 
with the findings of this study, whereby the odds of intradialytic hypotension were 
reduced with a step ramp compared to a linear ramp. This is most likely due to a longer 
period of increased plasma osmolarity that promoted vascular refilling. There is in 
theory a price to be paid with a potential of chronic sodium loading driving thirst, 
chronic water expansion and increasing interdialytic weight gain. In this study no long 
term data pertaining to interdialytic symptoms or weight gain was measured.   
 
The RBV at the point of decompensation shows large intra-patient and inter-patient 
variability but the vascular refilling capacity is always proportionately higher when the 
interstitial volume is expanded. This provides the rationale for UF profiles. Donauer et 
al reported a reduction in symptomatic hypotension episodes on profiles with decreasing 
UF rates with time on HD81. The outcomes of this study have been less favourable, I 
found no difference between profiling and a constant UF rate in preventing intradialytic 
symptoms or hypotension and in fact found that UF profile 2 reduced the odds of 
achieving the desired dry weight. The mean UF volumes were greater in the UF profile 
groups compared with treatments applying constant UF rates, but the gain was 
insufficient to increase the ability to achieve the desired dry weight. These contradictory 
results may be a reflection of the small sample size that was under-powered to reveal 
small differences. Alternatively the results are valid and are indicative of the problem of 
high UF rates that are characteristic to UF profiles. These periods of higher than average 
UF rates, or variable duration may exceed the body’s capacity to compensate, offering 
very limited reserve for variations in refilling capacity and thus at best only achieve 
minor gains in dialysis quality. In truth attempting to address the issue of large UF goals 
with techniques focusing on UF rates alone without consideration to refilling rates are in 
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reality destined to fail. In comparison automated RBV biofeedback techniques or more 
simply, RBV driven algorithms89 that adjust UF rates according to RBV changes are 
successful in achieving equivalent or higher UF volumes with reduced cardiovascular 
instability.  
 
Mannitol is a drug traditionally used in the management of dialysis disequilibrium as it 
can artificially increase plasma osmolarity. In prevalent dialysis patients, treatments 
prescribed mannitol achieved the highest mean UF volumes coupled with a significant 
reduction in the odds of symptoms, hypotensive episodes and the premature 
discontinuation of dialysis. Such positive outcomes were mirrored in the patients prone 
to hypotension. Mannitol requires dilution in saline prior to administration. Every 10g 
of mannitol is diluted in 100mls of normal saline and thus concurrently delivers 
15mmol of sodium to the intravascular compartment during the infusion. Therefore one 
could simply attribute its benefits to the fluid bolus that is inadvertently given and the 
increased gross UF volumes could be the result of filtering this fluid load. The counter-
argument to this is that the benefits of mannitol exceed that of a saline bolus. Mannitol 
also differs in the fact that it is an osmotically active solute that unlike sodium does not 
leak into the interstitium and thus provides a more sustained oncotic effect. On a note of 
caution this osmotic effect could theoretically be counter-productive as it runs a risk of 
inducing thirst in the interdialytic period with resultant escalating hypervolaemia. An 
alternative explanation to mannitol’s success is that it successfully treated milder 
degrees of disequilibrium, thus allowing treatments to proceed to completion. The true 
incidence of dysequilibrium is unknown but children, by virtue of their age, are deemed 
high risk. One patient also had an additional risk from co-existing neurological disease. 
It is also conceivable that within this context, the benefits of mannitol may have been 
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more pronounced as children are less likely to communicate symptoms until they are 
severe. 
 
Abnormal baroreflex sensitivity, altered vascular physiology, reduced coronary flow 
reserve are integral to cardiovascular decompensation during dialysis150, 154. The 
resultant effect is failure to preserve the central blood volume and myocardial 
dysfunction secondary to a reduction in global and regional myocardial blood flow65. 
During HD, UF activates sympathetic vasoconstriction, reducing skin blood flow and 
therefore heat exchange, with a direct correlation between UF volume and the amount 
of heat gained97. During isolated filtration there is significant cooling over the 
extracorporeal circuit and this attenuates the increase in core temperature98, 155. In 
patients prone to hypotension short-periods of sequential dialysis reduced intradialytic 
symptoms and half of the patients achieved their dry weight by the end of dialysis, but 
the risk of hypotension was unchanged. If we are to believe that the benefits of 
sequential dialysis are related to cooling then one can understand how short bursts of 
isolated UF have limited gain as the remainder of the dialysis time is spent at dialysate 
temperatures of 37.5˚C. This would negate any changes in core temperature that may 
have been achieved during sequential dialysis. Furthermore it is probable that with 
longer periods of sequential dialysis or by reducing the dialysate temperatures during 
the remainder of the treatment outcomes may have improved further. 
 
Midodrine was not part of the study protocol but was used as rescue therapy in one of 
the patients and hence deserves to be part of this discussion. Midodrine is a prodrug of 
desglymidodrine, a specific a-1 adrenergic agonist that increases intradialytic BP by 
mediating constriction of both arterial and venous capacitance vessels, thus preventing 
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venous pooling while supporting central BP.  Oral administration in our patient 
achieved peak levels within 1hr and I saw no evidence of prolonged hypertension 
beyond the period of dialysis in spite of pharmacokinetic data indicating a half-life of 
3hrs. Minor adverse reactions such as scalp paraesthesia, heartburn, flushing, headache, 
weakness and neck soreness have been described156 but no such adverse effects were 
witnessed. Adult nephrologists have the greatest experience with midodrine and report 
variable success but our results mirror those of Blowey et al reporting a benefit in an 18 
year old157. This single experience in a very difficult patient was very encouraging and 
certainly places midodrine in a position of priority for future research.  
 
 
5.6 Study Limitations 
The patient cohort was a small, heterogeneous group. In addition by virtue of the study 
protocol the exposure to the different interventions also varied between patients 
reducing intervention specific numbers further. Therefore my findings may be a 
reflection of the fact that the study was underpowered for small differences between the 
interventions and the results may have been different in a larger cohort. In a bid not to 
restrict numbers further all prevalent dialysis patients were recruited, including those 
with congenital heart defects. We know that the structural and physiological properties 
of the cardiovascular system are susceptible to change with disease. All of the cardiac 
patients were found to be susceptible to intradialytic symptoms and hypotension and 
hence they may have introduced a bias in the study of prevalent dialysis patients. Their 
inclusion within the second study with other high risk patients was probably more 
appropriate and encouragingly the results were no different. In paediatric HD, the 
prevalent dialysis patients tend to be children unsuitable for peritoneal dialysis, with 
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several co-morbidities, therefore even from the very onset of this study a selection bias 
was introduced. This also raises an important question on whether the baseline risk for 
cardiovascular compromise in prevalent HD patients differs from stable uncomplicated 
uraemic children. 
 
Within the study protocol it was impossible to control the UF prescription per dialysis 
treatment as this would have compromised patient well being. However there is a clear 
relationship between UF volumes and the risk of intradialytic morbidity. The problem is 
confounded further by the fact that tolerance to UF varies between patients and between 
treatments as illustrated in Chapter 3. Therefore even if statistical adjustments of the 
analyses for UF volumes were attempted this bias could not have been eliminated in this 
study.   
 
This is a preliminary study and being conscious of time and the relatively quick 
turnover of patients within paediatric dialysis units I did not elect to introduce 
interventions separately. For example sodium ramping was part of the standard 
prescription in the study of patients prone to hypotension and was used in combination 
with the UF profiles in the prevalent dialysis patients study. As a consequence it is hard 
to know whether the results achieved were exclusively attributable to the intervention in 
question or due to the synergistic effect of all the interventions that were present per 
dialysis treatment. 
 
Finally on a number of occasions in the discussion I have raised concerns of the long 
term effects of some of these interventions such as sodium profiling and intradialytic 
mannitol and the theoretical risk of chronic volume expansion. Follow up within this 
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study was short and data primarily concentrated on the intradialytic period and not the 
interdialytic period. In the battle against UF failure, preventative measures that limit salt 
and water intake are equally important, if not more important than intradialytic 
strategies aimed at treating salt and water excess. The lack of data on the long-term 
consequences of these interventions is a shortcoming of this study and is certainly an 
area thus needs to be explored in future studies. 
 
 
5.7 Conclusion 
During standard 4 hour HD regimens the evidence for the cardiovascular burden of HD 
is growing stronger and with it the urgency for change in the way we dialyse our 
patients. Improving dialysis failure is essential for patient well-being and will only be 
achieved following a better understanding of the underlying mechanism. Through a 
multidirectional approach, utilising strategies that improved plasma refilling and 
supported the central blood volume I have demonstrated an attenuated risk of 
intradialytic morbidity in both prevalent dialysis patients and children that are prone to 
hypotension. In our most resistant case oral midodrine was the only viable rescue 
option, nonetheless experience with midodrine in paediatrics is still very limited and its 
efficacy needs to validated in larger, randomised trials prior to recommending it for 
general use. 
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Chapter Six 
Thesis Summation 
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Paediatric HD patients are typically children that are unsuitable for home peritoneal 
dialysis, the default mode of dialysis, owing to social and/or medical co-morbidities. 
Whether this translates to a higher baseline risk of cardiovascular disease is unknown 
but what has become apparent from this research are the similarities in adverse 
outcomes related to in-centre, conventional HD sessions between children and adult HD 
patients. 
 
During conventional 4 hour paediatric HD treatments the prevalence of intradialytic 
hypotension ranged between 20-30%, a rate that is comparable to adult HD patients. In 
an attempt to restore euvolaemia at the end of each of their dialysis treatments UF goals 
as high as 9% of the dry weight were successfully attempted in the children but this was 
associated with a RBV reduction of 30%. More commonly UF goals of up to 6% of the 
dry weight were prescribed and this resulted in a marked inter- and intra-patient 
variability of RBV change that was not predictive of the onset of adverse intradialytic 
events. This supports the concept that decompensation during HD is not just related to 
changes in intravascular blood volume but other factors are also important. Tachycardia, 
a signal for the onset of compensatory mechanisms, and the severity of RBV change 
during the first hour of dialysis were significantly predictive of impending intradialytic 
symptoms or hypotension. 
 
 It is clear from this data that conventional HD places a significant haemodynamic stress 
on the child and one that triggers compensatory cardiovascular mechanisms aimed at 
maintaining circulation adequacy. However the nature of these responses varied 
between the patients studied. Nonetheless a pattern emerged. The cardiac output was 
more dependent on a chronotropic response than ionotropic response while the 
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intradialytic BP mirrored changes in peripheral vascular resistance. This also raised a 
suspicion that uraemic children have an attenuated ability to increase myocardial 
contractility during the course of HD.  
 
In children aged between 1 and 17 years there is functional and biochemical evidence of 
cardiac injury during conventional 4hour HD manifesting as transient, regional LV 
myocardial dysfunction in association with an elevation of plasma cardiac enzymes in 
one quarter of patients. The degree of dysfunction was related to the UF volume and 
intradialytic blood BP. In addition the percentage decline in LV function in the 
longitudinal axis was predictive of changes in systolic BP during dialysis. I postulate 
that the characteristic cardiovascular phenotype in HD patients predisposes to 
significant demand ischemia as illustrated in Figure 6.1. Conventional 4 hours HD is 
associated with increasing tachycardia and hypotension with a potential to cause an 
acute fall in coronary blood flow. Ordinarily this physiological stress is met and 
overcome by a complex network of autoregulatory mechanisms within the coronary 
circulation that supports and maintains an appropriate blood supply to the heart.  
However owing to the underlying constellation of cardiovascular disease that is 
typically found in uraemic children, the coronary reserve flow is impaired. Thus in the 
presence of an increased metabolic demand, such as dialysis, the limited ability to 
increase the oxygen supply to the heart results in a demand supply mismatch. Ischaemia 
prevails and this manifests as regional myocardial dysfunction. Owing to the design of 
the study it is impossible to decipher what factor takes the leads, the hypotension or the 
myocardial dysfunction. Regardless of the initiator, it is highly probable that the two are 
self-perpetuating.  
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The technique of speckle tracking 2D strain was superior to assessments of regional 
wall motion activity in detecting acute abnormalities in regional myocardial function. 
2D speckle tracking was both angle and translation independent and was therefore less 
influenced by intra-observer variability between images, improving its accuracy. It also 
provided two parameters of assessments, the peak strain and inter-segmental 
synchronicity index. The latter is particularly sensitive in detecting ischeamic cardiac 
injury and therefore in this setting has the potential for becoming a screening tool, 
looking for early evidence of dialysis induced cardiac injury and with it a window of 
opportunity to intervene before the myocardial injury becomes severe.  
 
The evidence for the cardiovascular burden of HD is growing stronger and with it the 
urgency for change in the way we dialyse our patients. Armed with greater details of the 
altered physiological responses during dialysis, a more directed approach to managing 
intradialytic morbidity is conceivable. During paediatric HD, patients are largely able to 
mount a tachycardic response but support is required to increase peripheral vascular 
resistance, expand the central blood volume and augment myocardial contractility. 
Sodium profiles and intradialytic mannitol encourage plasma refilling, sequential 
dialysis prevents blood from being diverted away from the central blood volume and 
midodrine increases vascular resistance. All four interventions were shown to be 
effective in moderating intradialytic symptoms and hypotension, midodrine and 
sequential dialysis exclusively in high risk, hypotension prone patients.    
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All the research that has been reported in this thesis is based on studies of a small 
cohort of HD patients from a single centre. First and foremost the results require 
validation from larger scale, long-term studies. The haemodynamic study (Chapter 
3) would benefit from a larger population base as this will allow the patients to be 
divided into relevant groups based on urine output, underlying renal disease and 
baseline risk of decompensation. These are factors that are likely to influence the 
compensatory response during dialysis and any information gained will provide 
additional insight into any variations that exist and help direct focused strategies to 
improve HD related morbidity.  
 
The study examining the myocardial effects of dialysis (Chapter 4) was limited to 
the acute effects on the heart from single dialysis sessions. However both adult 
dialysis data and the model of coronary artery disease allude to the progressive 
nature of myocardial stunning. This strengthens the case for gaining long-term 
follow up data in children. In addition data following them longitudinally once they 
change renal replacement therapy, such as transplantation will provide invaluable 
information on the degree of reversibility of dialysis induced myocardial injury and 
the risk of myocardial injury between the different forms of renal replacement 
therapies.  
 
The dialysis intervention study (chapter 5) measured the efficacy of various dialysis 
interventions in modifying intradialytic symptoms and prevalence of hypotension. 
One battle that is in the forefront of all nephrologists is that of salt and water 
balance. However in order to win, strategies have to be directed towards the 
interdialytic period as well as the intradialytic period that was exclusively examined 
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here. Interventions such as sodium profiles and intradialytic mannitol increase the 
osmotic load during dialysis and this may have a knock on effect on chronic fluid 
and BP management. Long-term follow up is required to ascertain the impact of 
these dialysis interventions on the immediate and late interdialytic period both in 
terms of patient symptoms and volume status. Furthermore this work could also be 
extended laterally by examining differences in RBV and dialysis induced 
myocardial dysfunction between the different interventions. Finally following on 
from the example set here and the success of midodrine in treating a very resistant 
case of intradialytic hypotension, its role in paediatric HD needs to be explored 
further. I would propose a randomised, cross-over trial of children prone to 
hypotension, supported by finometer, RBV change and regional myocardial function 
data.   
 
This thesis has introduced the concept of myocardial stunning in uraemic children 
and now additional work is necessary to understand the extent of the problem within 
the paediatric nephrology population base. The non-invasive technique of 2D 
speckle tracking lends itself well to these investigations.  
 I would like to start by investigating whether the chronicity of renal failure is 
important in medicating myocardial dysfunction. I plan to examine this by 
studying patients with acute renal failure on continuous renal replacement 
therapy.  
 At present it is difficult to know whether ‘uraemia’ or the haemodynamic stress 
related to dialysis is the dominant factor in dialysis induced myocardial 
dysfunction. Peritoneal dialysis (PD) is a gentler form of dialysis that is 
generally not associated with a large haemodynamic burden. An investigation of 
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children on PD would provide further insight on the relationship between 
uraemia and myocardial stunning.  
 At Great Ormond Street Hospital for Children, we have initiated plans to 
develop a paediatric home HD programme. Frequent HD has been shown to be 
superior to conventional HD both in fluid management, BP control, intradialytic 
haemodynamic stability and dialysis quality, but the mechanisms remain elusive. 
I would like to use this opportunity to explore the potential role of myocardial 
stunning in the reported cardiovascular advantages linked to this patient cohort.  
 Sequential dialysis utilizes the principle of cooling to improve cardiovascular 
stability during paediatric HD but is adversely association with sodium loading. 
Applied independently within conventional HD prescriptions, cooling of the 
dialysate has cardiovascular benefits but the duration and intensity of cooling is 
limited by the onset of symptoms related to feeling cold. I propose a 
randomised, cross-over study to determine the optimal paediatric dialysate 
temperature for abrogation of intradialytic morbidity without inducing adverse 
symptoms. This study could potentially provide a widely applicable and cost-
effective intervention for reducing the cardiovascular burden that children carry 
into adulthood.  
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List of Abbreviations 
 
2D   two-dimensional  
AHA  The American Heart Association 
ANCA  anti-neutrophil cytoplasmic antibodies 
ANOVA  one-way analysis of variance 
ARPKD  autosomal recessive polycystic kidney disease 
BNP  brain natriuretic peptide 
BP   blood pressure 
CRP  C-reactive protein  
cTnI  cardiac troponin-I 
cTnT  cardiac troponin-T 
CO   cardiac output 
CAD  coronary artery disease 
CKD  chronic kidney disease 
CI   confidence interval 
EF   ejection fraction 
ESRD  end stage renal disease 
FSGS  focal segmental glomerulosclerosis 
hsCRP  high sensitivity C-reactive protein 
HD  haemodialysis 
HR   heart rate 
IL-6  interleukin 6 
LV   left ventricle 
LVH  left ventricular hypertrophy 
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MBF  myocardial blood flow 
NIVM  non-invasive blood volume monitors 
PD   peritoneal dialysis 
PET  photon emission computed tomography 
ROC  receiver operating characteristics curve 
RBC  red blood cell 
RBV  relative blood volume 
RWMA  regional wall motion abnormalities 
SV   stroke volume 
TPR  total peripheral resistance 
UF   ultrafiltration 
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